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ABSTRACT

The presently disclosed subject matter relates to a method
for predicting increased risk of obesity on a non-obese
subject. More particularly, the presently disclosed subject
matter relates to a method of predicting increased risk of
obesity in a non-obese subject by determining a level of
neurotensin expression in a biological sample from the
subject and comparing the level of neurotensin expression in
the sample with a control level. The presently disclosed
subject matter further relates to a method of preventing
and/or treating obesity in a subject in need thereof by
administering to the subject an effective amount of an agent
that inhibits neurotensin.
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METHOD OF PREDICTING OBESITY
COMPRISING MEASURING NEUROTENSIN

This summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the feature(s) mentioned; likewise, those features can be applied to
other embodiments of the presently-disclosed subject matter, whether listed in this summary or not. To avoid excessive repetition, this summary does not list or suggest all
possible combinations of such features.
In some embodiments, the presently-disclosed subject
matter includes a method of predicting increased risk of
obesity in a non-obese subject, comprising contacting a
biological sample from the subject with a probe for neurotensin to determine the amount of neurotensin in the biological sample; comparing the amount of neurotensin to a
control level; and determining that the subject has an
increased risk of obesity if there is a measurable difference
in the amount of neurotensin in the sample as compared to
control level, wherein an increased neurotensin level is
predictive of an increased risk of becoming obese. In one
embodiment, the method further comprises measuring the
phosphorylation level of AMPK in the biological sample;
and comparing the measured phosphorylation level to a
control level, wherein a decreased level of phosphorylation
level is predictive for an increased risk of becoming obese.
In another embodiment, the biological sample comprises
blood, plasma, serum, plasma, and tissue. In a further
embodiment, the risk of becoming obese is independent of
baseline body mass index.
In some embodiments, the neurotensin is pro-neurotensin,
which may be detected by a technique comprising RNA
measuring assays and protein measuring assays. One suitable RNA measuring assay comprises real time reverse
transcription polymerase chain reaction. The obesity may
include, but is not limited to, prevalent obesity, prevalent
abdominal obesity, and/or new-onset obesity. Additionally
or alternatively, the method further comprises administering
to the non-obese subject preventative treatment for obesity.
In one embodiment, the preventative treatment includes
administration of a neurotensin inhibitor.
In some embodiments, the presently-disclosed subject
matter includes a method of detecting reduced intestinal fat
absorption in a subject, comprising contacting a biological
sample from the subject with a probe for neurotensin to
determine the amount of neurotensin in the biological
sample; comparing the amount of neurotensin to control
level; and determining that the subject has reduced intestinal
fat absorption if there is a measurable difference in the
amount of neurotensin in the sample as compared to control
level, wherein a decreased neurotensin level is indicative of
reduced intestinal fat absorption. In one embodiment, the
method further comprises measuring the phosphorylation
level of AMPK in the biological sample; and comparing the
measured phosphorylation level to a control level, wherein
an elevated phosphorylation level is indicative of reduced
intestinal fat absorption.
In some embodiments, the presently-disclosed subject
matter includes a method of preventing and/or treating
obesity in a subject in need thereof, comprising administering to the subject an effective amount of an agent that
inhibits neurotensin. In one embodiment, the method further
comprises administering a pharmaceutically acceptable carrier. In another embodiment, the agent includes, but is not

RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional
Application Ser. No. 62/299,688, filed Feb. 25, 2016, the
entire disclosure of which is incorporated herein by this
reference.
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in the invention.
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TECHNICAL FIELD
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The presently disclosed subject matter relates to a method
for predicting increased risk of obesity on a non-obese
subject. More particularly, the presently disclosed subject
matter relates to a method of predicting increased risk of
obesity in a non-obese subject by determining a level of
neurotensin expression in a biological sample from the
subject and comparing the level of neurotensin expression in
the sample with a control level.

25

BACKGROUND

30

Obesity and its associated comorbid conditions are among
the most prevalent and challenging conditions confronting
the medical profession in the 21 st century. Estimates by the
World Health Organization indicate that over 1.7 billion
people worldwide are overweight (BMfa:25) or obese
(BMfa:30) with over 2.5 million deaths annually attributable
to obesity. In the U.S., adult obesity rates rose from 14% in
1978 to over 30% in 2000 with over 50% of Americans
projected to be obese in 2030. Common comorbidities of
over-nutrition and obesity include insulin resistance and the
development of hepatic steatosis (i.e., nonalcoholic fatty
liver disease, which is noted in about 75% of obese patients).
However, the mechanisms responsible for obesity and other
metabolic sequelae associated with overconsumption of
dietary fats are poorly understood.
The small intestine plays a central role in the control of
energy homeostasis through the digestion, absorption and
assimilation of ingested nutrients. Food ingestion is associated with the increased secretion of multiple gut peptides,
produced in specialized enteroendocrine cells scattered
along the length of the small bowel, that act on distant target
sites (e.g., liver, muscle and adipose tissue) to promote the
efficient uptake and storage of energy, and the regulation of
lipid and glucose homeostasis. While GI hormones can
regulate energy balance in a number of ways, the role that
gut hormones play in obesity and metabolic disorders is
poorly understood.
Accordingly, methods for predicting increased risk of
obesity in non-obese subjects is desirable.
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SUMMARY
The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
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limited to, a neurotensin inhibitor, a neurotensin receptor
antagonist, a small molecule, a peptide, and/or siRNA.
Further features and advantages of the presently-disclosed
subject matter will become evident to those of ordinary skill
in the art after a study of the description, figures, and
non-limiting examples in this document.

analyzed by western blotting (left panel). Densitometric
quantification of p-AMPK was normalized by total AMPK
and the graph demonstrates the fold change of p-AMPK vs.
saline (right panel, n=S). * p<0.05 vs. saline; t p<0.05 vs.
olive oil alone. G. Human small intestinal cells (FHs74Int)
(left panel) and RIE-1 cells (right panel) were treated with
the indicated concentrations of oleate for 1 h and lysates
were analyzed by western blotting. H. FHs 74 Int cells were
pre-treated with or without NT at different dose as indicated
for 30 min followed by combined treatment with oleate (0.1
mM) for 1 hand western blotting of cell extracts (left panel);
densitometric analysis of p-AMPK is from 3 separate
experiments and normalized to total AMPK; graph demonstrates the fold change of p-AMPK vs. BSA (right panel). *
p<0.05 vs. BSA; t p<0.05 vs. oleate alone. I. FHs74Int cells
transfected with NTRl (100 nM), NTR3 (20 nM), and
control (100 and 20 nM, respectively) for 3 d were treated
with oleate (0.1 mM) or BSA in the presence or absence of
NT (2 µM) for 1 hand cell extracts were analyzed as in (g).
J. FHs 74 Int cells were treated with or without NT (2 µM)
for 30 min followed by AICAR (1 mM) for 2 h and oleate
(0.1 mM) for 1 hand analyzed by western blot (left panel);
p-AMPK levels were determined as in (h) from 3 separate
experiments (right panel). * p<0.05 vs. BSA; t p<0.05 vs.
oleate alone; t p<0.05 vs. oleate+AICAR. K. FHs74Int cells
were treated with NT (2 µM) for 30 min followed by
addition of AICAR (1 mM) for another 3 h; cells were then
incubated with BSA or BODIPY® FL C 16 (C 16 ) for 15 min
and images taken by confocal microscopy. L. FHs74Int cells
transfected with LKBl, CaMKK2 and control (all 40 nM)
siRNAs for 3 d were treated with oleate (0.1 mM) or BSA
in the presence or absence of NT (2 µM) for 1 h and cell
extracts were analyzed as in (g). M. FHs74Int cells transfected with Flag-CaMKK2 and control vector for 48 h were
treated with or without oleate (0.1 mM) or NT (2 µM) and
analyzed by western blotting. p-AMPK levels were determined as in (g) from 3 separate experiments (right panel). *
p<0.05 vs. BSA in vector- and CaMKK2-transfected cells,
respectively; t p<0.05 vs. BSA in vector-transfected cells; t
p<0.05 vs. oleate in vector-transfected cells; # p<0.05 vs.
BSA in vector-transfected cells; & p<0.05 vs. NT alone in
vector-transfected cells; § p<0.05 vs. oleate+NT in vectortransfected cells. All data are mean+/-SD. Experiments in
vitro were at least repeated three times.
FIGS. 3A-G includes images and graphs showing NT
suppresses adenosine monophosphate-activated protein
kinase (AMPK) activation and promotes lipid accumulation
in Drosophila. A. Midguts from 7 d adults expressing
Gr36C-Gal4 (control, 100%, n=5)) or Gr36C-NT (93%,
n=15) were stained with Nile Red. B. Oenocytes on the basal
surface of the lateral epidermis of 3 rd instar larvae expressing Gr36C-Gal4 (control, 100%, n=15) or Gr36C-NT (93%,
n=15) were stained with Oil Red O (ORO) to monitor lipid
accumulation. C. Fat bodies attached to the salivary gland
from the 3 rd instar larvae expressing Gr36C-Gal4 (100%,
n=S) or Gr36C-NT (100%, n=S) were photographed using
DIC microscopy. D. Flies with the indicated genotypes were
treated with either normal food (NF) or high-fat diet (HFD),
and guts were stained with Nile Red to examine the accumulation of lipids (arrows). Shown here are representative
images from each group (n=5). E. NT was expressed by
voila-Gal4 and adult flies fed either NF or HFD were
subjected for triglyceride (TG) analysis and normalized with
protein concentration38 (n=25 per group). * p<0.05 vs. NF in
control- and NT-expressing flies, respectively; t p<0.05 vs.
NF in control-expressing flies; t p<0.05 vs. HFD in controlexpressing flies. F. Western blotting shown to monitor the

5

BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. lA-H includes images and graphs showing protective effects of neurotensin (NT)-deficiency on obesity and
comorbid conditions. A. Image (upper panel) and graph
(lower panel) comparing body weight of male Nr 1+ and
NT- 1- mice fed a high-fat diet (HFD). B. Image (upper
panel) and graph (lower panel) comparing body weight of
female Nr 1+ and NT- 1- mice fed a high-fat diet (HFD).
Representative images taken at 24 wks. Body weight (BW)
was measured weekly for 22 wks; BW slopes were compared: * p<0.05 NT+1+ vs. NT- 1- mice. Male NT+1+=l8 and
NT-1-=15 mice; 54.6 g vs. 42.9 g; female Nr1+=15 and
NT-1-=12 mice; 49.2 g vs. 35.9 g at the end time point. C.
Plasma glucose (upper panel) and insulin (lower panel)
levels quantified in 24 h-fasted male mice maintained on a
LFD or HFD for 24 wks (n=S-10); * p<0.05 vs. LFD in
NT+/+ and NT_;_ mice, respectively; t p<0.05 vs. HFD in
NT+!+ mice. D. Blood glucose (BG) during insulin tolerance
test (ITT) (left panel) and glucose tolerance test (GTT) (right
panel) in 6 h-fasted male mice fed a HFD for 24 wks
(n=3); * p<0.05 vs. NT_;_ mice. E. Gross, H&E and oil red
0 (ORO) imaging of livers of male mice fed a HFD for 24
wks (n=5). F. Hepatic triglyceride (TG) and cholesterol were
analyzed by liquid chromatography-mass spectrometry (LCMS) in 24 h-fasted male mice fed a HFD for 24 wks
(n=3). * p<0.05 vs. Nr 1+ mice. G. H&E staining of epididymal fat from male NT+/+ and NT- 1- mice fed a LFD or
HFD for 24 wks. H. Quantitative analysis of adipocyte area
(n=6). * p<0.05 vs. LFD in Nr 1+ and NT_;_ mice, respectively; t p<0.05 vs. LFD in Nr 1+ mice; p<0.05 vs. HFD in
NT+!+ mice. All data are mean+/-SD.
FIGS. 2A-M includes images and graphs illustrating NT
deficiency reduces intestinal lipid absorption. A. (left panel)
Fecal triglyceride (TG) was analyzed in male mice fed a
high-fat diet (HFD) for 24 wks (n=3); * p=0.05 vs Nr 1+
mice; (right panel) Fecal weight was measured in male
Nr 1+ and NT- 1- mice (n=7-9) fed either normal chow (NC)
or HFD for 24 wks; there was no significant difference
between genotypes. B. Oil red O (ORO) staining of proximal intestines from male mice (6-mo-old) under normal
chow fed with or without olive oil by gavage after overnight
fasting (n=3). C. Levels of 13 C 18 -oleic acid (OA) in male
mice (5-mo-old) under normal chow fed with 13 C 18 -OA
mixed in olive oil by gavage after an overnight fast was
analyzed by nanospray FT-MS (n=3-4). Left panel, * p<0.05
vs. NT+/+ mice. Right panel, *t p<0.05 vs. 0 h in NT+/+ and
NT_;_ mice, respectively; p<0.05 vs. 2 h and 3 h in NT+/+
mice. D. ORO staining of proximal intestines from male
mice (5-mo-old) following gavage with or without olive oil
plus NT after an overnight fast (left panel); TG was quantified (right panel) (n=5). * p<0.05 vs. Saline in Nr 1+ and
NT_;_ mice, respectively; t p<0.05 vs. olive oil in NT_;_
mice; t p<0.05 vs. olive oil in NT+/+ mice. E. Western blot
analysis of proximal intestinal mucosa from 24 h-fasted
male mice (12-mo-old) maintained on a normal chow (left
panel). Densitometric quantification of p-AMPK was normalized to total AMPK and is presented as fold change vs.
p-AMPK in Nr 1+ (right panel, n=9). * p<0.05 vs. Nr 1+. F.
Protein extracts from mucosa! scrapings of samples were
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levels of AMPK in adult midgut same as (A). G. MyolAGal4 combined with tub-Ga!S0's (Myo's) does not express
Gal4 at 20° C. permissive temperature. Shown in the left
panel is the midgut from a 7 d adult bearing Myo' -AMPK
raised at 20° C., stained with Nile Red, and used as a control
(100%, n=15). Midguts expressing AMPK (middle panel,
100%, n=15) or AMPK RNAi 25931 (right panel, 87%, n=15)
from 7 d adults at 29° C. were stained with Nile Red. The
levels of AMPK were monitored by western blot.
FIGS. 4A-J shows NT deficiency inhibits high-fat diet
(HFD)-induced obesity. A. Epididymal fat pad (arrows)
from male mice (5-mo-old) maintained on a normal chow
before dissection. B. Epididymal fat pad from male mice
(5-mo-old) maintained on a normal chow after dissection. C.
Retroperitoneal fat pad from male mice (5-mo-old) maintained on a normal chow (arrows). D. Representative epididymal (arrows) fat pads of male mice fed a HFD for 24
wks. E. Representative retroperitoneal fat pads of male mice
fed a HFD for 24 wks. F. Representative pericardia! fat pads
of male mice fed a HFD for 24 wks. G. Weekly body weight
changes of male and female mice placed on a LFD for 25
wks Male NT+!+ n=13 NT_;_ n=13 mice· female NT+/+
n=12, NT- 1- n=14 mice'. There is no statisti;al significance
between NT+!+ and NT_;_ in both male and female mice. H.
Fat composition was measured by EchoMRI in male mice
fed LFD or HFD for 24 wks (n=5). *p<0.05 vs. LFD fat;
tp<0.05 vs. Nr 1+ LFD fat; t p<0.05 vs. Nr 1+ HFD fat;
#p<0.05 vs. Nr 1+ HFD lean. I. H&E staining of epididymal
fat pad from male mice as in FIG. lg; arrows showing the
inflammatory cells. J. F4/80 IHC staining of epididymal fat
pad from HFD-fed mice as in FIG. lg; arrows showing
F4/80+ cells. All data are mean+/-SD.
FIGS. SA-G includes graphs showing NT deficiency does
not alter food intake, energy intake, energy expenditure,
locomotor activity and resting respiratory exchange ratio
(RER). A. Graphs showing cumulative food intake of male
(left panel) and female (right panel) mice fed LFD and HFD.
Analysis of cumulative food intake for 22 wks did not show
a significant difference except in female mice fed HFD
(p=0.04). B. Graphs showing weekly food intake of male
mice on LFD (left panel) and HFD (right panel). C. Graphs
showing weekly food intake of female mice on LFD (left
panel) and HFD (right panel). For weekly food intake, there
was no significant difference between genotypes in male
mice on both diets (B) and female mice fed LFD (C, left
panel); food intake on week 9 in female mice fed HFD
reached significance between genotypes (C, right panel). For
A-C, food intake was measured weekly for NT+/+ and NT_;_
male (LFD n=3 and HFD n=4) and female (LFD n=3 and
HFD n=4) mice. D. Energy expenditure of male mice on
LFD and HFD diets for 24 weeks, presented by the average
kcal/h in 24 h and in resting period. E. Locomotor activity
of male mice on LFD and HFD diets for 24 weeks, which
represents counts of beam breaks in a 30 min-period. F.
Energy intake of male mice on LFD and HFD diets for 24
weeks, which represents the food intake in kcal for 24 h. G.
Resting RER of male mice on LFD and HFD diets for 24
weeks. In D-G, male mice on LFD and HFD diets for 24 wks
were placed in individual cages and indirect calorimetric
analysis performed (n=l0).ANCOVAtest, * p<0.05 vs. LFD
in Nr 1+ mice; t p<0.05 vs. LFD in NT- 1- mice. All data are
mean+/-SD.
FIGS. 6A-C includes images and graphs illustrating Neurotensin receptor (NTR) expression in small bowel. A.
Expression ofNTRl (left panel) and NTR3 (right panel) was
analyzed by western blot from mucosa scraped from mouse
proximal (pro), middle (mid), distal (dis) small bowel and

colon as well as human duodenum (duo) and colon. Proteins
from HepG2 (a human hepatocellular carcinoma cell line)
and Caco-2 (a human colon cancer cell line) cells stably
expressing NTRl, NTR3, or control (NTC) shRNA were
used as positive and negative controls. B. IHC was performed on mouse proximal intestines for NTRl and NTR3
expression. C. Total RNA was isolated from human
(FHs74Int) and rat (RIE-1) small intestinal epithelial cells
and RT-PCR performed using specific primers targeting
human or rat NTRl, 2 and 3.
FIGS. 7A-E shows NT promotes intestinal cell lipid
absorption or accumulation. A. RIE-1 cells were pre-treated
with BSA or NT (2 µM) for 30 min and BSA-conjugated
BODIPY® FL C 16 was added and incubated for 15 min
followed by confocal microscopic analysis. B. RIE-1 cells
were pre-treated with or without NT at different concentrations for 30 min followed by the addition of BSA-conjugated oleate (0.1 mM) and further incubation overnight.
Cells were collected, lysed and Triglyceride (TG) was
measured (n=3). * p<0.05 vs. BSA only (-); t p<0.05 vs.
oleate only. C. RIE-1 cells transfected with non-targeting
control (NTC) siRNA or siRNA directed to either NTRl or
NTR3 for 72 h were treated with or without NT (2 µM) for
30 min followed by incubation of BSA-conjugated
BODIPY® FL C 16 (C 16 ) for 15 min. Images were taken by
confocal microscopy and green intensity quantified as
described in the methods section. n=30 cells; * p<0.05 vs.
cl6 in NTC siRNA; t p<0.05 vs. cl6 plus NT in NTC
siRNA. D. RIE-1 cells were pre-treated with or without NT
for 30 min followed by combined treatment by BSA or
BSA-conjugated oleate (0.1 mM) for 1 h and western blot
performed. E. RIE-1 cells were transfected with siRNA
directed to either NTC, NTRl (100 nM) (left panel) or
NTR3 (20 nM) (right panel) for 3 d, treated with NT (2 µM)
and oleate (0.1 mM) as in (d) and analyzed by western
blotting. All data are mean+/-SD. Experiments were
repeated at least three times.
FIGS. SA-G includes images illustrating NT regulates
lipid droplet accumulation and AMPK activation in Drosophila midgut, fat body, and oenocytes. A. Midgut from a 7
d adult expressing NT by Gr36C-Gal4 was stained for NT
and Prospero (Pros). Inset shows NT co localization with
Pros. B. Characterization of the Gr36C-Gal4 expression in
enteroendocrine cells. An adult midgut expressing GFP
under the control of Gr36C-Gal4 was collected from 7 d
adult flies raised at 25° C. normal temperature and stained
for GFP and Pros. Inset in the merged channel shows high
magnification image indicating colocalization of GFP with
Pros. C. Expression of NT promotes the accumulation of
lipid droplets. Left panel, a control midgut from 3 rd instar
larvae expressing Gr36C-Gal4 alone was stained with Nile
Red to label the lipid droplets (100%, n=7). Right panel, a
midgut expressing NT by Gr36C-Gal4 was stained with Nile
Red (93%, n=15). D. The entire gastrointestinal tracts from
larvae as in (c) bearing the indicated genotypes were lysed
and subjected to western blot analysis with the indicated
antibodies. E. Left panel, a midgut from 3 rd instar larva
bearing Myo's -AMPK raised at 20° C. stained with Nile Red
as control. Myo' -AMPKRNAi 25931 at 20° C. permissive
temperature showed similar Nile Red staining to that of
Myo' -AMPK at 20° C. Middle and right panels, midguts
expressing AMPK or AMPKRNAi 25931 under the control of
Myo's were collected from 3 rd instar larvae and stained with
Nile Red. Fly embryos bearing the indicated genotypes were
raised at 20° C. until 96 h AEL and then switched to 29° C.
nonpermissive temperature to induce Gal4 expression. The
overexpression and RNAi efficiency of AMPK were moni-
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tared with an anti-AMPK antibody from Cell Signaling
Technology by western blot analysis (not shown). Shown
here are representative images (n=7 for each group). F. The
RU486-dependent S106-Gal4 driver was used to overexpress or inhibit AMPK expression to examine lipid droplet
accumulation in fat bodies in 3 rd instar larvae. Representative DIC micrographs ofS106-Gal4-AMPK without RU486
(left panel, 100%, n=l0). Similar results were obtained for
S106-Gal4-AMPKRNAi 25931 without RU486), S106-Gal4AMPK with RU486 (200 µM in food, middle panel, 80%,
n=l0), and S106-Gal4-AMPKRNAi 25931 with RU486 (right
panel, 90%, n=l0). To achieve precise comparison, fat
bodies attached to the salivary glands from different genotypes were analyzed. G. As in (E), except that oenocytes
were stained with Oil Red Oto examine lipid accumulation,
genotypes and RU486 treatment are indicated. Compare
middle panel (80%, n=l0) and right panel (90%, n=l0) to
the left panel of control (100%, n=l0).
FIGS. 9A-C. LC-MS/MS analysis of the processed NT
peptide. A. The mass spectrum of the triply charged NT
(NT3+) peptide eluted at 18.96 min in conditioned medium
of S2 cells expressing full-length human NT precursor. The
labeled three peaks are the isotopic envelope of NT 3+ with
a mass accuracy less than 2 ppm from the theoretical m/z
value of 585.31050. B. The tandem mass spectrum of the
triply charged NT 3+ peptide. The m/z values of major
fragment ions are designated, confirming the peptide as
biologically active 13-amino acid NT. C. The amount of NT
in S2 medium and fly GI tracts (350 guts collected for each
sample) from adult Gr36C-NT flies was quantified (N.D.,
not detected).
FIGS. lOA-E shows CG9918 (mouse NTRl analog)
RNAi blocks the NT-mediated decrease of p-AMPK levels
in Drosophila S2 cells. A. S2 cells were transfected with
ub-Gal4 plus UAST-NT (ub-Gal4-NT) or control (ub-Gal4)
vector and treated with the indicated dsRNA to knockdown
individual receptors. Cell lysates were subjected to western
blot with the indicated antibodies to examine the activation
of AMPK (left panel). The efficiency of RNAi knockdown
was monitored by real time-PCR (middle panel). * p<0.05
vs. control dsRNA. Medium from cells expressing either
ub-Gal4 alone or ub-Gal4-NT was collected to examine the
levels of NT by NT EIA (right panel); * p<0.05 vs. ub-Gal4.
B. S2 cells were treated with the indicated concentrations of
NT peptide for 1 h and AMPK activation was monitored as
in (a). NT treatment (0.2, 0.5 µM) decreased p-AMPK to
levels similar to those observed in ub-Gal4-NT transfected
cells where NT levels reach approximately the same concentration (350 ng/ml, 0.2 µM). C. S2 cells were transfected
with ub-Gal4-NT or control vector and treated with the
indicated dsRNA and cell lysates were analyzed as in (a).
Inactivation of Capability (Capa, CG15520), the Pyrokinin-1 in Drosophila, alters the levels of p-AMPK in neither
the presence nor the absence of NT (left panel), indicating
that NT prevents AMPK activation independently of Pyrokinin. Capa RNAi efficiency was monitored by real timePCR (right panel).* p<0.05 vs. control dsRNA. D. Midguts
of 3 rd instar larvae from the indicated genotypes were
stained with Bodipy to monitor the accumulation of lipid
droplets. Left panel, wl 118 control midgut accumulates low
level of lipid (100%, n=8). Middle panel, larval midgut
constitutively expressing NT by the TK promoter (TK-NT)
accumulates high levels of lipid (100%, n=8). Right panel,
larval midgut co-expressing TK-NT and MyolACG9918RNAi27539 accumulated much lower levels of lipid
(87%, n=15) compared to TK-NT midgut (middle panel). E.
Amino acid sequence alignment of mouse NTRl (SEQ ID

NO: 1) and Drosophila CG9918 (SEQ ID NO: 2), identities
and conserved residues ( +) are indicated. All data are
mean+/-SD. Experiments in vitro were repeated at least
three times.
FIGS. llA-F show graphs illustrating that NT deficiency
does not affect body length or small intestine morphology. A.
Body length of both NT+!+ and NT_;_ mice was measured
and did not differ significantly between genotypes for either
male or female mice (n=l2-13/genotype/sex). B. Average
weight of the small intestine for male NT+/+ and NT_;_ mice
(n=7/genotype). C. Average length of the small intestine for
male Nr 1+ and NT_;_ mice (n=7/genotype). D. H&E staining of proximal intestinal samples from male NT+/+ and
NT- 1- mice (bar=50 µm). E. Villus height measurements
from proximal intestinal samples of male NT+/+ and NT_;_
mice, which show no significant differences between genotypes. F. Crypt number measurements from proximal intestinal samples of male NT+/+ and NT_;_ mice, which show no
significant differences between genotypes. Mice (7 months)
for all experiments were maintained on standard chow after
weaning and all data are plotted as mean+/-SD.
FIGS. 12A-C show graphs and images illustrating that NT
deficiency improves insulin/Akt signaling and reduces adipocyte inflammation. A. NT+/+ and NT_;_ mice fed LFD or
HFD for 22 wks after weaning were fasted overnight. Saline
or insulin (5 units) was injected into the IVC. Five min after
the injection, liver tissues were collected and protein extracts
analyzed by western blot. A representative result is shown
from 3 separate experiments. B. Male NT+!+ and NT- 1- mice
(7-mo-old) fed standard chow after weaning were fasted
overnight followed by glucose (2 mg/kg) administration by
gavage (n=5/genotype). Blood samples were collected both
prior to and at the indicated times after glucose administration for measurement of plasma insulin (left panel) and
glucose (right panel) levels. No statistically significant differences in either insulin or glucose levels were apparent
between genotypes. C. Male NT+!+ and NT_;_ mice (12-moold) fed standard diet after weaning were fasted for 16 h or
fasted for 16 hand refeed for 4 h (n=3/genotype). Blood was
collected from IVC and plasma used to measure insulin. *
p<0.05 vs. fasted NT+/+ mice.
FIGS. 13A-D show graphs and images illustrating that
NT promotes intestinal cell lipid absorption or accumulation, while NT deficiency reduces intestinal lipid absorption
A. Proximal intestines from mice given saline, olive oil, or
olive oil+SR 48692 were collected and TG levels quantified
as described above (n=8). Graph presents the fold change vs.
control mice. * p<0.05 vs. control mice; t p<0.05 vs. mice
with olive oil only. B. Male Nr 1+ and NT_;_ mice (n=4) on
normal chow were fasted overnight. Mice were injected with
either saline or SR 48692 (2.5 mg/kg, i.p). Thirty min after
the injection, mice were given olive oil (10 µ1/g) by oral
gavage and then sacrificed. The proximal small bowel was
excised and TG content measured. *p<0.05 vs. saline in
NT+/+ and NT- 1- mice; t p<0.05 vs. olive oil only in NT+/+
mice; t p<0.05 vs. olive oil only in Nr 1+ mice. C. Weekly
body weight was measured in male wild type C57BL/6 mice
fed HFD and treated with SR 48692 (2.5 mg/kg diluted in
diH 20 and administered by oral gavage twice a day) or
vehicle (vehicle n=12; SR 48692 n=13). BW slopes were
compared: * p<0.05 vehicle vs. SR treatment. D. Weekly
food intake was measured in male wild type C57BL/6 mice
(n=l2-13) fed HFD and chronically treated with either SR
48692 or vehicle. Analyses of either cumulative (left panel)
or weekly (right panel) food intake did not show a significant
difference. All data are mean+/-SD.
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FIGS. 14A-C show graphs and images illustrating that
FFA activates AMPK signaling and increases NT secretion.
A. Plasma NT of male C57BL/6 mice (5-mo-old, n=5) 1 h
after olive oil (00) oral gavage. *p<0.05 vs. NC; n=5. B.
NT EIA (upper panels) and western blotting (lower panels)
on BON cells treated with or without OA for 1 h. C. NT EIA
(upper panels) and western blotting (lower panels) on
QGP-1 cells treated with or without OA for 1 h. *p<0.05 vs.
control; n=6. All data are mean+/-SD.
FIGS. 15A-B show graphs and images illustrating that
FFARl and FFAR4 agonists increaseAMPK activity. A. NT
IF (left panel), NT EIA (middle panel, *p<0.05 vs. control)
and western blotting (right panel) of STC-1 cells. B. Realtime PCR. GAPDH was used as the internal control (BON
cell expression was arbitrarily set at 1). All data are mean+/SD.
FIGS. 16A-D show graphs and images illustrating Crosstalk of AMPK and mTORCl signaling. A. Diagram of
cross-talk of AMPK and mTORCl signaling. B. Western
blot analysis of BON cells treated with or without AICAR
(left panel) or 1 mM AICAR and CC (10 µM) (right panel)
for 3 h. C. NT EIA (upper panel) and western blotting (lower
panel) on BON cells expressing control vector and mycraptor S722A/S792A treated withAICAR (1 mM) for 3 h. D.
NT EIA (upper panel) and western blotting (lower panel) on
BON cells expressing control vector and NTC and TSC2
siRNA treated with AICAR (1 mM) for 3 h. *p<0.05 vs.
control in vector, tp<0.05 vs. AI CAR in vector (C); *p<0.05
vs. control in NTC siRNA, tp<0.05 vs. control in NTC
siRNA, t p<0.05 vs. AICAR in NTC siRNA (D). n=6. All
data are mean+/-SD.

methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a," "an," and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some
embodiments ±0.1 % from the specified amount, as such
variations are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently disclosed subject matter relates to a method
for predicting increased risk of obesity in a non-obese
subject. More particularly, the presently disclosed subject
matter relates to a method of predicting increased risk of
obesity in a non-obese subject by determining a level of
neurotensin expression in a biological sample from the
subject and comparing the level of neurotensin expression in
the sample with a control level.
In some embodiments of the presently disclosed subject
matter, a method of predicting increased risk of obesity in a
non-obese subject is provided. The method includes the
steps of contacting a biological sample from the subject with
a probe for neurotensin to determine the amount of neurotensin in the biological sample; comparing the amount of
neurotensin to a control level; and determining that the
subject has an increased risk of obesity if there is a measurable difference in the amount of neurotensin in the sample
as compared to a control level, wherein an increased neurotensin level is predictive for an increased risk of becoming
obese.
In some embodiments, the method further includes the
steps of measuring the phosphorylation level of AMPK in
the biological sample; and comparing the measured phosphorylation level to a control level, wherein a decreased
level of phosphorylation is predictive for an increased risk of
becoming obese. A non-limiting example of neurotensin is
pro-neurotensin. In some embodiments of the presently
disclosed subject matter, the risk of becoming obese is
independent of baseline body mass index (BMI).
As used herein, the term "obesity" or "obese" refers to a
medical condition in which excess body fat has accumulated
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The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
Some of the polynucleotide and polypeptide sequences
disclosed herein are cross-referenced to GENBANK®/
GENPEPT® accession numbers. The sequences cross-referenced in the GENBANK®/GENPEPT® database are
expressly incorporated by reference as are equivalent and
related sequences present in GENBANK®/GENPEPT® or
other public databases. Also expressly incorporated herein
by reference are all annotations present in the GENBANK®/
GENPEPT® database associated with the sequences disclosed herein. Unless otherwise indicated or apparent, the
references to the GENBANK®/GENPEPT® database are
references to the most recent version of the database as of
the filing date of this Application.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
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to the extent that it may have an adverse effect on health,
leading to reduced life expectancy and/or increased health
problems. Obesity is typically determined by assessing the
body mass index (BMI), a measurement which compares
weight and height. For example, people are often defined as
underweight if BMI is below about 18, normal if BMI is
between about 18 and 25, overweight if their BMI is
between about 25 and 30, and obese when BMI is greater
than about 30. The term "non-obese" refers to underweight,
normal, and overweight.
The phrase "predicting increased risk" as used herein
refers to methods by which the skilled artisan can predict the
course or outcome of the treatment for a condition in a
subject. It does not refer to the ability to predict the course
or outcome of a condition with 100% accuracy, or even that
a given course or outcome is predictably more or less likely
to occur based on the presence, absence or levels of test
biomarkers. Instead, the skilled artisan will understand that
the term refers to an increased probability that a certain
course or outcome will occur; that is, that a course or
outcome is more likely to occur in a subject exhibiting a
given condition, when compared to those individuals not
exhibiting the condition (e.g., biomarker level). For
example, in individuals not exhibiting the condition, the
chance of a given outcome may be about 3%. In certain
embodiments, a prognosis is about a 5% chance of a given
outcome, about a 7% chance, about a 10% chance, about a
12% chance, about a 15% chance, about a 20% chance,
about a 25% chance, about a 30% chance, about a 40%
chance, about a 50% chance, about a 60% chance, about a
75% chance, about a 90% chance, or about a 95% chance.
The skilled artisan will understand that associating a
prognostic indicator with a predisposition to an adverse
outcome is a statistical analysis. For example, a biomarker
level (e.g., quantity of expression in a sample) of greater
than a control level in some embodiments can signal that a
subject is more likely to develop obesity in a non-obese
subject than subjects with a level less than or equal to the
control level, as determined by a level of statistical significance. Additionally, a change in marker concentration from
baseline levels can be reflective of subject prognosis, and the
degree of change in marker level can be related to the
severity of adverse events. Statistical significance is often
determined by comparing two or more populations, and
determining a confidence interval and/or a p value. See, e.g.,
Dowdy and Wearden, Statistics for Research, John Wiley &
Sons, New York, 1983, incorporated herein by reference in
its entirety. Preferred confidence intervals of the present
subject matter are 90%, 95%, 97.5%, 98%, 99%, 99.5%,
99.9% and 99.99%, while preferred p values are 0.1, 0.05,
0.025, 0.02, 0.01, 0.005, 0.001, and 0.0001.
In other embodiments of the presently-disclosed subject
matter, a threshold degree of change in the level of a
prognostic or diagnostic biomarker can be established, and
the degree of change in the level of the indicator in a
biological sample can simply be compared to the threshold
degree of change in the level. A preferred threshold change
in the level for markers of the presently-disclosed subject
matter is about 5%, about 10%, about 15%, about 20%,
about 25%, about 30%, about 50%, about 75%, about 100%,
and about 150%.
In certain embodiments, a diagnostic or prognostic biomarker is correlated to a condition or disease by merely its
presence or absence. In other embodiments, a threshold level
of a diagnostic or prognostic biomarker can be established,
and the level of the indicator in a subject sample can simply
be compared to the threshold level.

The "amount" oftest biomarker(s) determined refers to a
qualitative (e.g., present or not in the measured sample),
quantitative (e.g., how much is present), or both measurement of the text biomarker(s) (e.g., neurotensin). The "control level" is an amount (including the qualitative presence
or absence) or range of amounts of biomarker(s) found in a
comparable biological sample in non-obese subjects who did
not become obese. In some embodiments, the control level
can refer to reference value or a standard sample that is
provided based on information obtained about the amounts
of the biomarker(s) found in comparable biological
sample(s) from non-obese subjects who did not become
obese.
As used herein, the term "subject" refers to an animal,
including a mammal, such as a human being.
With regard to the step of providing a biological sample
from the subject, the term "biological sample" as used herein
refers to any body fluid or tissue potentially comprising the
presently-disclosed biomarkers, including neurotensin. In
some embodiments, for example, the biological sample can
be a blood sample, a serum sample, a plasma sample, or
sub-fractions thereof. In some embodiments, the biological
sample is an adipose tissue biopsy, such as a tissue biopsy
containing adipocytes or cells suspected to be adipocyte.
Turning now to the step of identifying one or more
markers in the biological sample, various methods known to
those skilled in the art can be used to identify the one or
more markers in the provided biological sample. In some
embodiments, determining the amount of biomarkers in
samples comprises using an RNA measuring assay to measure mRNA encoding biomarker polypeptides in the sample
and/or using a protein measuring assay to measure amounts
of biomarker polypeptides in the sample.
In certain embodiments, the amounts of biomarkers can
be determined by probing for mRNAofthe biomarker in the
sample using any RNA identification assay known to those
skilled in the art. Briefly, RNA can be extracted from the
sample, amplified, converted to cDNA, labeled, and allowed
to hybridize with probes of a known sequence, such as
known RNA hybridization probes (selective for mRNAs
encoding biomarker polypeptides) immobilized on a substrate, e.g., array, or microarray, or quantitated by real time
PCR (e.g., quantitative real-time PCR). Because the probes
to which the nucleic acid molecules of the sample are bound
are known, the molecules in the sample can be identified.
With regard to determining amounts of biomarker polypeptides in samples, in some embodiments, mass spectrometry and/or immunoassay devices and methods can be used
to measure biomarker polypeptides in samples, although
other methods are well known to those skilled in the art as
well. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,
944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,
527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and
5,480,792, each of which is hereby incorporated by reference in its entirety. Immunoassay devices and methods can
utilize labeled molecules in various sandwich, competitive,
or non-competitive assay formats, to generate a signal that
is related to the presence or amount of an analyte of interest.
Additionally, certain methods and devices, such as biosensors and optical immunoassays, can be employed to determine the presence or amount of analytes without the need for
a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and
5,955,377, each of which is hereby incorporated by reference in its entirety.
Thus, in certain embodiments of the presently-disclosed
subject matter, the marker peptides are analyzed using an
immunoassay. The presence or amount of a marker (e.g.,
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neurotensin or pro-neurotensin) can be determined using
antibodies or fragments thereof specific for each marker and
detecting specific binding. For example, in some embodiments, the antibody specifically binds pro-neurotensin,
which is inclusive of antibodies that bind the full-length
peptide, fragments thereof, or phosphorylated forms thereof.
In some embodiments, the antibody is a monoclonal antibody.
Any suitable immunoassay can be utilized, for example,
enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like. Specific immunological binding of the antibody to the marker
can be detected directly or indirectly. Direct labels include
fluorescent or luminescent tags, metals, dyes, radionuclides,
and the like, attached to the antibody. Indirect labels include
various enzymes well known in the art, such as alkaline
phosphatase, horseradish peroxidase and the like.
In some embodiments, the amount of pro-neurotensin is
detected by a technique comprising RNA measuring assays
and protein measuring assays. In some embodiments, an
RNA measuring assay comprises real time reverse transcription polymerase chain reaction.
In some embodiments, the obesity is prevalent obesity. In
some embodiments, the obesity is prevalent abdominal
obesity. In some embodiments, the obesity is new-onset
obesity.
Further provided in some embodiments of the presently
disclosed subject matter, is a method of administering to
non-obese subject preventative treatment for obesity. In
some embodiments, the preventative treatment includes
administration of a neurotensin inhibitor.
In some embodiments, the presently disclosed subject
matter further provides a method of detecting reduced
intestinal fat absorption in a subject. The method includes
the steps of contacting a biological sample from the subject
with a probe for neurotensin to determine the amount of
neurotensin in the biological sample; comparing the amount
of neurotensin to a control level; and determining that the
subject has reduced intestinal fat absorption if there is a
measurable difference in the amount of neurotensin in the
sample as compared to the control level, wherein a
decreased neurotensin level is indicative of reduced intestinal fat absorption. In some embodiments, the method further
includes the steps of measuring the phosphorylation level of
AMPK in the biological sample; and comparing the measured phosphorylation level to a control level, wherein an
elevated phosphorylation level is indicative of reduced intestinal fat absorption.
Still further, in some embodiments of the presently disclosed subject matter, a method of preventing and/or treating
obesity in a subject in need thereof is provided. The method
includes administering to the subject an effective amount of
an agent that inhibits neurotensin. In some embodiments, the
method further includes administering a pharmaceutical
composition including an agent that inhibits neurotensin and
a pharmaceutically acceptable carrier. In some embodiments, the agent is a neurotensin inhibitor. In some embodiments, the agent is a neurotensin receptor antagonist. In
some embodiments, the agent is a small molecule. In some
embodiments, the agent is a peptide. In some embodiments,
the agent is neurotensin siRNA.
Non-limiting examples of neurotensin receptor antagonists are those disclosed in Gully et al., 1993 and Gully et al.,
1997, including SR 48692 and SR 142948A. Gully et al.,
1993, and Gully et al., 1997 are incorporated by reference in
their entirety.

As used herein, the terms "treatment" or "treating" relate
to any treatment of a condition of interest, including but not
limited to prophylactic treatment and therapeutic treatment.
The terms relate to medical management of a subject with
the intent to substantially cure, ameliorate, stabilize, or
substantially prevent a condition of interest (e.g., disease,
pathological condition, or disorder), including but not limited to prophylactic treatment to preclude, avert, obviate,
forestall, stop, or hinder something from happening, or
reduce the severity of something happening, especially by
advance action.
As such, the terms treatment or treating include, but are
not limited to: inhibiting the progression of a condition of
interest; arresting or preventing the development of a condition of interest; reducing the severity of a condition of
interest; ameliorating or relieving symptoms associated with
a condition of interest; causing a regression of the condition
of interest or one or more of the symptoms associated with
the condition of interest; and preventing a condition of
interest or the development of a condition of interest.
The terms includes active treatment, that is, treatment
directed specifically toward the improvement of a condition
of interest, and also includes causal treatment, that is,
treatment directed toward removal of the cause of the
condition of interest. In addition, the terms includes palliative treatment, that is, treatment designed for the relief of
symptoms rather than the curing of the condition of interest;
preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development
of the associated condition of interest; and supportive treatment, that is, treatment employed to supplement another
specific therapy directed toward the improvement of the
associated condition of interest.
Neurotensin (NT), a 13-amino acid peptide, or tridecapeptide, predominantly localized in specialized enteroendocrine (EE) cells of the small bowel and released by fat
ingestion, facilitates fatty acid (FA) translocation in rat
intestine, and stimulates growth of various cancers. NT,
which is released from N-cells of the small bowel in
response to intraluminal fats, facilitates free fatty acid (FFA)
absorption from the intestinal lumen, stimulates pancreaticobiliary secretions, decreases gastric motility, and contributes to lipid metabolism and glucose control, although its
precise role in these processes has not been previously
delineated. The effects of NT are mediated through three
known NT receptors (NTRl, 2 and 3). Increased fasting
plasma levels of pro-NT (a stable NT precursor fragment
produced in equimolar amounts relative to NT) are associated with increased risk of diabetes, cardiovascular disease
and mortality; however, a role for NT as a causative factor
in these diseases is unknown. In the past, NT has been
considered as a satiety hormone which could potentially
curb appetites. Therefore, previous studies have proposed
using NT analogues, instead of inhibitor, as a possible
treatment for obesity. However, in some embodiments of the
presently disclosed subject matter, a preventive and/or treatment method for obesity is provided by administering agents
that blocks the effects of neurotensin.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the presently disclosed subject matter.
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EXAMPLES

old) were obtained from Taconic. After one week acclimation, mice were placed in individual cages, started on HFD,
and after one week were divided into 2 groups one of which
received SR 48692 (dissolved in sterile diH 2 0 by brief
sonication, 2.5 mg/kg body weight 31 - 33 and the other vehicle
twice/day (8 am and 8 pm) by gavage. Mice were weighed
and food intake was measured weekly.
Human Intestinal Samples.
Surgical samples of duodenum and colon were obtained
from de-identified donors through the Markey Cancer Center Biospecimen and Tissue Procurement Shared Resource
Facility. All samples were obtained after informed consent
according to a protocol approved by the Institutional Review
Board of the University of Kentucky Medical Center
(UKMC). Freshly-resected duodenum and colon specimens
were placed in cold (4° C.) Dulbecco's Modified Eagle's
Medium (DMEM) (Sigma-Aldrich) supplemented with 10%
fetal bovine serum (FBS) (Sigma-Aldrich), 2% penicillin/
streptomycin (20,000 U/mL penicillin, 20 mg/mL streptomycin) (Sigma-Aldrich), and 1.0 µg/mL Fungizone (Life
Technologies). Tissues were processed within one hour after
resection; the mucosa! layer was sharply dissected from the
underlying seromuscular layer and collected in multiple 3 to
5 mm sections for western blotting.
Cell Culture.
FHs74Int, purchased from ATCC (Manassas, Va.), is a
human small intestinal epithelial cell line maintained in
Hybri-Care Medium ATCC 46-X supplemented with 30
ng/ml epidermal growth factor (Sigma-Aldrich) and 10%
FBS. RIE-1 is a rat intestinal epithelial cell line maintained
in DMEM containing 2 mM L-glutamine, 4500 mg/L glucose and 10% FBS. The human colon cancer cell line,
Caco-2 (ATCC), is maintained in Minimum Essential
Medium (MEM) (Sigma-Aldrich) supplemented with 15%
FBS. The human liver cancer cell line, HepG2 (ATCC), is
maintained in MEM with 10% FBS. FHs 74 Int cells were
tested for authentication via STR profiling in April 2015 by
Genetica DNA Laboratories (LabCorp Specialty Testing
Group; Burlington, N.C.) using the commercially available
PowerP!ex® 16HS amplification kit (Promega Corporation)
and GeneMapper ID v3.2.1 software (Applied Biosystems).
Authentication was confirmed by a 100% match in comparison to the reference STR profile fromATCC (FHs 74 Int;
ATCC® CCL-241™). The cell lines are not listed in the
ICLAC database. In addition, both cell lines were tested for
mycoplasma contamination via PCR (e-Myco Plus kit;
iNtRON Biotechnology) and were found to be negative.
Western Blotting.
Tissues and cells were lysed with lysis buffer (Cell
Signaling Technology), and equal amounts of protein were
resolved on 4-12% NuPAGE BisTris gels (Life Technologies) and electrophoretically transferred to polyvinylidene
difluoride (PVDF) membranes; the membranes were incubated with primary antibodies overnight at 4° C. followed by
secondary antibodies conjugated with horseradish peroxidase. Membranes were developed using chemiluminescence
(ECL) Western Blotting System from GE Healthcare Life
Science (Piscataway, N.J.) and Thermo Scientific (Waltham,
Mass.).
Histology and Immunohistochemistry (IHC).
Epididymal adipose, liver and intestinal tissues were fixed
in 10% neutral-buffered formalin, embedded in paraffin, and
sectioned (5 µm). H&E staining was performed using standard techniques. Adipocyte size was measured as described
previously. Briefly, sections of epididymal adipose tissue
from each mouse were photographed under xl00 magnification. In a square measuring 700x700 µm (x- and y-axis,

Example 1
The current study shows that NT-deficient mice demonstrate significantly reduced intestinal fat absorption and are
protected from obesity, hepatic steatosis, and insulin resistance associated with high fat consumption. It further demonstrates that NT attenuates the activation of AMP-activated
protein kinase (AMPK) and stimulates FA absorption in
mice and in cultured intestinal cells, and that this occurs
through a mechanism involving NTRl and NTR3/sortilin in
vitro. Consistent with the findings in mice, expression of NT
in Drosophila midgut EE cells results in increased lipid
accumulation in the midgut, fat body, and oenocytes (specialized hepatocyte-like cells) and decreasedAMPK activation. In humans, this study shows that both obese and
insulin-resistant subjects have elevated plasma concentrations of pro-NT, and in longitudinal studies among nonobese subjects, high levels of pro-NT denote a doubling of
the risk of developing obesity later in life. This study directly
link NT with increased fat absorption and obesity and
suggest that NT may provide a prognostic marker of future
obesity and a potential target for prevention and treatment.
Methods
Reagents.
Antibodies for p-AMPKa (2535), AMPKa (2532), and
LKBl (3050) were from Cell Signaling Technology (Danvers, Mass.). Antibodies for NTRl (sc-374492 for western
blotting and sc-25042 for IHC) and NTR3 (sc-30217 for
IHC) were from Santa Cruz Biotechnology (Dallas, Tex.).
CaMKK2 (ab168818), NTR3 (ab166490 for western blotting), and F4/80 (ab100790) antibodies were from Abeam
(Cambridge, Mass.). FLAG (F1804) and ~-actin (A5316)
antibodies were from Sigma-Aldrich (St. Louis, Mo.). ONTARGETplus SMARTpool (LKBl, CaMKK2, NTRl,
NTR3) and ON-TARGETplus Non-targeting Control Pool
siRNA were purchased from GE Dharmacon (Lafayette,
Colo.). AICAR was from Cayman (Ann Arbor, Mich.).
Oleate sodium, NT, glucose and human insulin were from
Sigma. Deuterated oleic acid (CLM-460-PK) was obtained
from Cambridge Isotope Laboratories (Tewksbury, Mass.).
SR 48692 was from Tocris (Minneapolis, Minn.). siRNA
(RNAiMAX) and plasmid (Lipofectamine® LTX Reagent
with PLUS™ Reagent) transfection reagents, and Trizol
were from Life Technologies (Grand Island, N.Y.). pSG5FLAG-CaMKK2 rat FL was a gift from Anthony Means
(Addgene plasmid #32449) (Cambridge, Mass.). Primers for
RT-PCR were from Integrated DNA Technologies (Coralville, Iowa).
Mice.
All procedures were approved by the Institutional Animal
Care and Use Committee of the University of Kentucky. NT
homozygous (NT- 1-) mice and their wild type littermates
(NT+ 1+) were bred from NT heterozygous (NT+ 1-) mice and
randomly grouped for all experiments. Mice were maintained on 12-h light-dark cycles and provided with food and
water ad libitum. For diet-induced obesity studies, male and
female NT+!+ and NT-1- mice were placed on a 60% HFD or
10% LFD (catalogue no. D12492 and D12450B, respectively; Research Diets, New Brunswick, N.J.) at weaning for
22-25 wks. Body weight and food intake were measured
weekly. Food intake was measured for each cage (3-5 mice
per cage) and divided by mouse number to obtain total
grams consumed per mouse per week. All mice used were
4-6 months old unless otherwise indicated. For chronic SR
48692 treatment on HFD-fed mice, C57BL/6 mice (8 weeks
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respectively), adipocyte size and number were measured
using NIS Elements BR.3.10 software. A criterion for inclusion of measurements was a circularity of adipocytes superior to 0.33 [shape of cells; from O (thin shape) to 1 (perfect
circle)]. For oil red O (ORO) staining, liver and small bowel
tissues were fixed in 10% neutral-buffered formalin, equilibrated in 30% sucrose and embedded in OCT compound and
snap-frozen in liquid N 2 . Frozen sections were stained with
ORO (Sigma-Aldrich) for lipid deposition using standard
methods. IHC was performed and visualized by Dako EnVision Systems (Burlington, Ontario, Canada) following the
product instruction.

NT Enzymeimmunoassay (EIA).
Fifty µl of media were used to measure NT levels using
NT EIA Kit from Phoenix Pharmaceuticals (Burlingame,
Calif.) as described previously30 - 33 .
Glucose and Insulin Tolerance Tests.
Glucose (GTT) and insulin (ITT) tolerance tests were
performed on 6 h-fasted mice fed HFD. Glucose values were
measured using One Touch Ultra from LifeScan (Wayne,
Pa.) by tail snip. Glucose (1.5 g/kg body weight) and human
insulin (0.75 U/kg body weight) were injected intraperitoneally (i.p.) after baseline glucose levels established in each
mouse. Glucose was measured at 15, 30, 60 and 120 min
after injection.
Metabolic Studies.
Whole body composition parameters were measured by
EchoMRI-5000 Whole Body Composition (Echo Medical
System, Houston, Tex.) using Magnetic Resonance Relaxometry to precisely measure total body fat, lean mass, body
fluids and total body water in conscious mice. A TSE
LabMaster indirect calorimetry system (TSE-Systems Inc.,
Chesterfield, Mo.) was used to simultaneously quantify
energy expenditure, energy intake, locomotor activity, and
respiratory exchange ratio (RER). Mice were acclimated to
the chambers for 7 d, to permit recovery from the weight loss
initially experienced by obese mice. Recordings were performed for 5 d, yielding three full 24 h periods of data.
Feeding and activity data were collected continuously; 0 2
and CO 2 levels for energy expenditure and RER calculations
were collected at 30 min intervals. Resting energy expenditure values were calculated from data collected between 9
AM and 6 PM, filtered to remove points at which activity
was greater than 150 counts for that interval.
For hepatic triglyceride and cholesterol measurements,
liver tissues were collected and triglyceride and cholesterol
extracted as described previously and analyzed by LC-MS
coupled with electrospray ionization tandem using stable
isotope dilution performed on AB Sciex 4000 Q-Trap instruments. Plasma glucose was analyzed using a Glucose Colorimetric Assay Kit (BioVision, Inc., Milpitas, Calif.) and
insulin using a Mouse Insulin ELISA kit (Mercodia Inc,
Winston Salem, N.C.). Plasma insulin and glucose levels
were measured in mice (fed standard chow after weaning)
that had been fasted overnight and subsequently given
glucose (2 g/kg body weight) by gavage (i.e., oral glucose
tolerance test). Blood was collected from tail snips before (0
min) or 15, 30, 60 and 120 min after gavage. Insulin and
glucose levels were measured as described above. Plasma
insulin levels were also determined in mice that were either
fasted for 16 h or fasted for 16 h with refeeding for 4 h;
blood was collected from the IVC. For fecal triglyceride
assay, mice were housed in individual cages for 4 d; day 4
fecal samples were dried and ground. Lipid was extracted
from 50 mg of fecal samples and triglyceride measured by
LC-MS and normalized to fecal weight.
Body Length Measurements.
Anal-nasal length was measured following isoflurane
anesthesia of NT+/+ and NT_;_ mice.
Fecal Weight Measurements.
NT+/+ and NT- 1- mice fed HFD for 24 wks were separated
into individual cages and fecal pellets were collected and
weighed daily for 4 d. Fecal weights from day 4 were
averaged for wild type and NT deficient mice.
Small intestinal characterization. The entire small intestine (SI), from the gastric pylorus to the ileocecal valve was
dissected from anesthetized male NT_;_ and NT+/+ mice.
The SI length was measured and then opened longitudinally,
washed in cold saline to clear the luminal contents, dried

Reverse transcription-polymerase chain reaction (RTPCR). Total RNA was isolated from cells using RNeasy Kit
(Qiagen, Valencia, Calif.) according to the manufacturer's
instructions. RT-PCR analysis of NTRl, 2 and 3 was performed using cDNA synthesized from 1 µg of total RNA.
~-actin was used as the internal control. The primers
included: human NTRl:
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(SEQ ID NO, 3)
5'-TCATCGCCTTTGTGGTCTGCT-3'
and
25
(SEQ ID NO, 4)
5'-TGGTTGCTGGACACGCTGTCG-3';
human NTR2,
(SEQ ID NO, 5)
5'-GTCTCCTCAGCTTCATCGTAT-3'
30
and
(SEQ ID NO, 6)
5'-TCCCCAAAGCCTGAAGCTGTA-3';
human NTR3

(SORTl),

(SEQ ID NO, 7) 35
5'-AGAATGGTCGAGACTATGTTG-3'
and
(SEQ ID NO, 8)
5'-AAGAGCTATTCCAAGAGGTCC-3';
40

rat ntrl:
(SEQ ID NO, 9)
5'-GAGAAGCCCCCAAAATTCTC-3'
and

(SEQ ID NO, 10)
45
5'-CAAGGACCCAGTGCAGGTAT-3';
rat ntr2:
(SEQ ID NO, 11)
5'-ACTCGCTCATCTTCGCATTT-3'
and
50

(SEQ ID NO, 12)
5'-TGGGACCACACGAAGTTGTA-3';
rat ntr3

(Sortl),

(SEQ ID NO, 13)
5'-TTTCAAGCTGTGCTTTGTGG-3'
55
and
(SEQ ID NO, 14)
5'-AGTTCTCTGAACGGGAGCAA-3'.
13-actin,

60

(SEQ ID NO, 15)
5'-TCACCAACTGGGACGACATG-3'
and
(SEQ ID NO, 16)
65
5'-ACCGGAGTCCATCACGATG-3'.

The PCR products were analyzed on a 2% agarose gel.
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briefly on a paper towel and weighed. The SI was divided 5
cm distal from the pyloric junction and the jejunoileum was
divided into equal proximal and distal fragments. Proximal
fragments were fixed in 10% neutral-buffered formalin for
24 h, and "Swiss rolls"41 were sectioned (5 µm) for H&E and
IHC staining. H&E stained sections were imaged on an
Aperio ScanScope XTTM slide scanner at 20x. Crypt counts
and villus height were determined using Aperio ImageScope
vll.2.0.780 software. Crypts in a 1 mm field were quantified; 10 fields were analyzed per section. Villus height was
measured from 10 well-oriented villi on each slide.
Lipid Absorption Studies.
For olive oil administration and ORO analysis, mice were
fasted overnight and fed the olive oil (17 µ1/g body weight)
by gavage. The mice were sacrificed before (control), 30 min
and 60 min after the gavage. The intestine was resected from
the ligament of Treitz to the ileocecal junction, divided into
proximal, middle, and distal segments of equal length and
washed with cold saline. The proximal intestine was processed for frozen sections and ORO staining by standard
protocol.
For 13 C 18 -OA experiments, mice were fasted overnight
and fed 13 C 18 -OA (480 µM/g body weight) mixed in olive
oil (10 µ1/g body weight) by gavage. Mice were sacrificed at
0 and 30 min after gavage. Proximal intestines were collected. To detect plasma level of 13 C 18 -OA, mice were
given 13 C 18 -OA as above and blood was collected from tail
snip before (0 h), 1, 2 and 3 h after gavage. Lipid was
extracted from proximal intestines and plasma and analyzed
for 13 C 18 -OA enrichment by direct infusion nanospray FTMS (Orbitrap Fusion™ Tribrid™ Mass Spectrometer,
Thermo Scientific, Waltham, Mass.) modified from a previous method. Briefly, aliquots of the lipid extracts were first
diluted twenty-fold in isopropanol:chloroform:methanol
4:2:1 before introduction into TriVersa NanoMate® (Advion, Inc., Ithaca, N.Y.) and analyzed on the Orbitrap Fusion
in negative ion mode to estimate the appropriate amount of
d34-OA to spike. Lipid extracts spiked with known concentration of d 34-OA in the same solvent system were analyzed
again with the same FT-MS method. The nanospray conditions on the Nanomate were as follows: 15 µl of sample
injection, 16 min of delivery time, 0.4 psi of gas pressure,
and 1.5 kV of negative applied voltage. The Orbitrap Fusion
MS analysis conditions were as follows: mass resolution of
450,000 with lock mass using internal calibrant, scan range
of m/z 150-1600, % S-Lens RF Level of 60, 1.0e5 for AGC
Target, 100 msec maximum injection time, and 10 averaged
microscans. The ion transfer tube temperature was 275° C.,
and the experimental mass accuracy was ±-1 ppm. The
unlabeled, 13 C labeled, and d34 -OA were assigned based on their
respective accurate mass of 281.24860, 299.30899, and
314.45574; unlabeled and 13 C labeled OA were then quantified against the internal d 34-OA standard using their
respective peak intensity.
For NT "rescue" experiments, mice were fasted overnight
and fed with or without the olive oil (17 µ1/g body weight)
by gavage followed by i.p. injection of saline or NT (3600
nmol/kg body weight) immediately after gavage. The mice
were sacrificed 60 min after the gavage. Partial proximal
intestine was processed for ORO staining as described above
and partial for triglyceride quantification using a Triglyceride Determination Kit (Sigma-Aldrich) 38 .
For in vitro FA absorption or lipid accumulation studies,
FHs7 4Int and RIE-1 cells were incubated with either bovine
serum albumin (BSA) (Sigma-Aldrich) or BSA-conjugated
BODIPY® FL C 16 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,
4a-Diaza-s-Indacene-3-Hexadecanoic Acid) (Life Technolo-

gies) for 15 min. BSA-conjugated oleate sodium was also
used to treat cells for 1 h; cells were then stained with
BODIPY® 493/503 (4,4-Difluoro-l ,3,5,7,8-Pentamethyl-4Bora-3a,4a-Diaza-s-Indacene) (Life Technologies). Images
were observed under an FVl000 Olympus confocal microscope with a x60, 1.35-numerical aperture oil objective
(Olympus, Tokyo, Japan). Images were analyzed with
Olympus FV10-ASW2.1 software. To quantify green intensity, 3 images were taken at consistent conditions and 10
cells from each image were analyzed using the area tool. For
the lipid accumulation study, RIE-1 cells were pre-treated
with or without NT at different concentrations for 30 min
followed by combination of NT with BSA or BSA-conjugated oleate (0.1 mM) overnight. Cells were collected, lysed
and triglyceride content was measured by Triglyceride
Determination Kit (Sigma-Aldrich). All experiments were
carried in serum-free medium and fatty acid-free BSA was
used at 0.1%.
For acute SR 48692 treatment, male wild type C57BL/6
mice (16 weeks old) obtained from Taconic (Hudson, N.Y.)
were acclimated for one week, randomly divided into control, olive oil, and olive oil+SR 48692 groups (n=8) and
fasted overnight. SR 48692 was dissolved in DMSO (50
mg/ml) and diluted 1:100 in saline just prior to use. Mice
were injected i.p. with SR 48692 (2.5 mg/kg) 31 •33 or vehicle
30 min prior to oral gavage of olive oil (10 µ1/g), sacrificed
after an additional 30 min, and the distal half of the proximal
intestine (see above) was used to determine TG content and
for preparation of lysates for western blotting. This experiment was repeated in male NT+/+ and NT- 1- mice (7-moold), and proximal intestinal TG was measured as described
above.
Drosophila Studies.
Full-length human NT cDNA was inserted into an attBUAST backbone and the resultant transgene generated using
an attP2 locus and PhiC31 integration system. UAS-AMPK
and UAS-AMPKRNAi (v106200) lines have been
described. UAS-AMPKRNAi line was also obtained from
Bloomington Stock Center (TRiP #25931). These RNAi
(TRiP #25931 and vl 06200) gave rise to similar phenotypes,
thus AMPKRNAi 25931 was used for most of the experiments. Gr36C-Gal4, MyolA' -Gal4, voila-Gal4, and S106Gal4 have been described (FlyBase). MyolA-Gal4 is specifically expressed in enterocytes. In order to constitutively
express NT in gut EE cells, a gut EE cell-specific TK
promoter (2.0 kb )28 •29 was cloned into attB-UAST lacking
Gal4 binding sites followed by insertion of full-length NT
cDNA and the resulting plasmid (TK-NT) was used to
generate a transgenic line by insertion at the VK5 attP locus.
To express NT in EE cells and knock down CG9918 by
RNAi in EC cells, the following genotype was used: yw;
MyolA-Gal4/CG9918RNAi 27539 ; TK-NT/+. The tubGal80's was used in combination with the MyolA-Gal4
(resulting in the genotype of Myo's) to temporarily control
MyolA-Gal4 target gene expression, after shifting larvae to
29° C. nonpermissive temperature 96 h after egg laying
(AEL) or adult emerging. The present inventors combined
the AMPK or AMPKRNAi allele with the RU486-inducible
GeneSwitch Gal4 line: S106-Gal4, which is fat body-specific. Then, the present inventors grew larvae with either
S106-AMPK or S106-AMPKRNAi to vehicle or RU486
(200 µM, Mifepristone, Sigma-Aldrich) containing food and
examined the accumulation of lipid droplets in fat body or
oenocytes from 3 rd instar larvae. Fresh food was supplied
every other day. For midgut immunostaining, midguts from
3 rd instar larvae or adults with specific genotypes were
dissected in PBS then fixed with 4% formaldehyde in PBS
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for 20 min. After permeabilization with PBT (PBS supplemented with 0.1% Triton Xl00), midguts were incubated
with the indicated primary antibodies for 3 h and the
corresponding secondary antibodies for 1 h sequentially, and
washed with PBT for 3 times, 20 min per wash, following
incubation. Antibodies used in this study: mouse anti-Pros
(DSHB, MRlA); rabbit anti-NT (Abeam, ab43833). Midgut
staining with Nile Red (Sigma-Aldrich) and larvae staining
with Oil Red O (Sigma-Aldrich) were carried out after
fixation.
For western blot analysis, 15 entire gastrointestinal tracts
from each genotype were lysed in SDS sample buffer [100
mM NaCl, 50 mM Tris.RC! [pH8.0], 1.5 mM EDTA, 10%
glycerol, 1% NP-40, and protease inhibitor tablet (Roche,
Indianapolis, Ind.)], and resolved by SDS-PAGE and transferred to PVDF membranes (Millipore). Membranes were
blocked and probed with primary antibodies to phosphoAMPKa (Cell Signaling, #2535), total AMPKa (Abeam,
ab80039,), and ~-tubulin (DSHB, E7, Iowa City, Iowa).
After wash and incubation with secondary antibody (Jackson ImmunoResearch, West Grove, Pa.), signals were
detected using ECL.
The method of HFD feeding for adult flies has been
described. Briefly, flies (5 d after emerging) were collected
and placed in bottles of normal food (cornmeal-yeast) and
aged for an additional 5 d. This population was then split
into two study groups, one on normal food and one on the
HFD containing 20% (weight-to-volume ratio) coconut oil
with the normal food. Flies were treated on HFD for 5 d.
Treated adult flies were dissected and stained with Nile Red
to examine lipid accumulation in the midgut. The other
group of flies expressing NT by the EE cell-specific voilaGal4 was subjected to triglyceride measurement (SigmaAldrich) after being given either HFD or normal food.
voila-Gal4-wl 118 flies were used as control for this triglyceride experiment. Both male and female flies showed similar
results in triglyceride concentration, which was increased by
HFD.
Drosophila S2 cells were cultured as previously
described. dsRNA was synthesized against GFP (nucleotides
6-606), CG9918 (nucleotides 11-570), CG8784 (nucleotides - 72-478), CG8795 (nucleotides -203-343), and Capa
(nucleotides 1-455) by the method described. Total RNA
was extracted using Trizol reagent (Invitrogen). cDNA was
synthesized using SuperScript III First Strand Synthesis kit
(Invitrogen) from 1.0 µg total RNA according to the manufacturer's instructions. Quantitative RT-PCR reactions were
carried out using SYBR Green PCR master mix reagents
(Thermo) on the ABI StepOneP!us Real-Time PCR System
(Applied Biosystems). Thermal cycling was conducted at
95° C. for 30 sec, followed by 40 cycles of amplification at
95° C. for 5 sec, 55° C. for 30 sec and 72° C. for 15 sec. The
relative quantification of gene expression for each sample
was analyzed by the llCt method. The following primers
were used to amplify:
CG9918,
5'-GAGTTTCAACGGCGGAGGAA-3'
and
5'-AGCAGAGGAAGAAGCACACC-3',
CG8784,
5'-GGCGTGCTGGGTAATCTTAT-3'
and

-continued
CG8795,
5'-GCTACGCCCTCATATTTATC-3'
and
5

5'-GAGGTTATAGAGGTCCTGCG-3',
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(SEQ ID NO, 17)
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(SEQ ID NO, 18)

(SEQ ID NO, 19)

(SEQ ID NO, 20)

(SEQ ID NO, 23)

5'-CCAACGCGCGGGAAGGC-3',

(SEQ ID NO, 24)

15 5'-AAGCTGCAACCTCTTCGTCA-3'

20

(SEQ ID NO, 22)

Capa,
5'-ATGAAATCTATGTTGGTC-3'
and

Actin:
5'-GCGTCGGTCAATTCAATCTT-3'
and

65

5'-CAAAGGTTGTACAGCTCCTG-3',

(SEQ ID NO, 21)

(SEQ ID NO, 25)

(SEQ ID NO, 26).

NT Enzyme Immunoassay (EIA).
Fifty µI of media from S2 cells transfected with ub-Gal4
and UAST-NT were used to measure NT levels using NT
EIA Kit from Phoenix Pharmaceuticals (Burlingame, Calif.)
as described previously.
LC-MS/MS Analysis of NT.
NT was analyzed by liquid chromatography tandem mass
spectrometry (LC-MS/MS) using an LTQ-Orbitrap mass
spectrometer (Thermo Fisher Scientific, Waltham, Mass.)
coupled with an Eksigent Nanoflex cHiPLC™ system (Eksigent, Dublin, Calif.) through a nano-electrospray ionization
source. NT in the NT EIA kit (Phoenix Pharmaceutical) was
used as standard. S2 cells were transfected with ub-Gal4 and
UAST-NT or the UAST vector control, and conditioned
medium was harvested after 48 h for analysis. GI tracts
(350/genotype) were dissected from wild-type (w1118) or
Gr36C-NT 3 rd instar larvae, methanol extracted, extracts
were dried, and dissolved in 20 µI 0.1 % (v/v) formic acid in
water for analysis. Samples were separated by reversed
phase cHiPLC [ChromXP C18 column, 75 µm I.D.x15 cm
length, Eksigent cat#804-00001; mobile phase A and B were
0.1 % (v/v) formic acid in either water or acetonitrile, respectively; flow rate, 300 nl/min]. LC-MS/MS data were
acquired in an automated data dependent acquisition mode
consisting of an Orbitrap MS scan (300-1800 m/z, 60,000
resolutions) followed by MS/MS for fragmentation of the 7
most abundant ions with the collision induced dissociation
method. MS/MS fragments corresponding to NT 1 - 13 were
identified by comparison with the NT standard, and quantified using the intensity of the NT 3 + peak and NT standards
(0.05, 0.1, 0.2, 0.5 fmole).
Human Population Studies.
The Malmo Diet and Cancer (MDC) study is a population-based, prospective epidemiologic cohort of28,449 men
(born 1923-1945) and women (born 1923-1950) from the
city of Malmo in southern Sweden who underwent baseline
examinations between 1991 and 1996. From this cohort,
6,103 persons were randomly selected to participate in the
MDC Cardiovascular Cohort (MDC-CC), which was
designed to investigate the epidemiology of carotid artery
disease, between 1991 and 1994. Fasted plasma samples at
the baseline examination were available for analysis of
pro-neurotensin (pro-NT) and successfully measured in a
total of 4,632 participants in the MDC-CC. Of those, complete data were available for BMI in 4,626, for waist
circumference on 4,625, and for estimated degree of insulin
resistance using the homeostasis model assessment of insu!in resistance (HOMA-IR) (fasting blood glucose concentrationxfasting plasma insulin concentration/22.5) in 4,468
participants. BMI was defined as body weight in kilograms
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divided by the square of height in meters and obesity as a
BMh:30 kg/m2 . Abdominal obesity was defined as a waist
circumference of 2:94 cm in males and 2:80 cm in females,
according to the International Diabetes Federation definition. Insulin resistance was regarded present in subjects
belonging to the top 25% of HOMA-IR values in the
MDC-CC. 'New-Onset Obesity' is defined as obesity development among non-obese MDC-CC participants who were
re-examined and diagnosed with obesity after an average
follow-up time of 16.5±1.5 years. Pro-NT was measured in
stored fasting plasma specimens that were frozen to -80° C.
immediately at the MDC-CC baseline exam using a recent
chemiluminometric sandwich immunoassay to detect a proNT precursor fragment (pro-NT 1-117) as described previously. Analyses of blood glucose and plasma insulin were
carried out at the time of baseline examination at the
Department of Clinical Chemistry, Malmo University Hospital, which is attached to a national standardization and
quality control system. Of the 4,626 subjects with baseline
data on BMI and pro-NT, 2,900 subjects were re-examined
with a new measurement of BMI after a mean follow-up of
16.5±1.5 years. In analyses of incident obesity, the present
inventors excluded 306 subjects who were obese already at
the baseline examination, leaving a total of2,594 non-obese
subjects for analysis of pro-NT in relation to incident
obesity. All participants gave written informed consent, and
the study was approved by the Ethical Committee at Lund
University, Lund, Sweden.
Statistical Analysis.
Descriptive statistics including means and standard deviations were calculated and represented using bar graphs.
Linear mixed models were implemented to compare body
weight and food intake levels over time as well comparisons
at each time point for other endpoints from in vivo experiments involving repeat measurements. Specifically, body
weight growth curves were compared using linear mixed
models with fixed effects for linear and quadratic terms for
time and their interaction with genotype and random effects
for the intercept and time factors. Contrast statements for the
interaction terms in the model were used to assess differences in growth curves between genotypes. Likewise, linear
mixed models were employed for body weight growth curve
comparisons between vehicle versus SR 48692 with the
same fixed and random effects terms as above along with
baseline weight as a covariate. Total food consumption for
22 weeks was calculated and compared between genotypes
and between vehicle versus SR 48692 treatment using
two-sample t-tests. Furthermore, weekly food intake levels
were analyzed using linear mixed models. However, since
there is no clear trend in weekly food intake over time, an
overall comparison of trend was not employed. Instead, a
linear mixed model with fixed effects for genotype, time and
their interaction and a random effect for the intercept term
was employed in order to perform individual comparisons at
each time point. A p-value adjustment due to multiple testing
at each time point was performed using the Holm's stepdown procedure. We used the Akaike Information Criterion
(AIC) to evaluate the goodness-of-fit of the above linear
mixed models. One-way or two-way analysis of variance
models with test for interaction between two factors was
employed for multiple group comparisons of diet (LFD,
HFD), mouse genotype, feeding and fasting groups, different time points of measurement, and varying doses of NT
treatment, SR 48692 and AI CAR treatments with contrasts
generated to perform pairwise comparisons. Analysis of
covariance was employed to compare genotype and diet
with adjustment for the confounding effect of mouse body

weight for fat composition and energy metabolism endpoints
(energy expenditure, locomotor activity, energy intake,
respiratory ratio). Model-building was performed to assess
equality of slopes using two-way interactions between each
of genotype and diet with the covariate as well as genotype
and diet interactions. Two-sample t-test or the nonparametric
analog was employed for cell culture and in vivo studies
involving two independent groups.
For the animal studies, sufficient sample sizes were utilized to provide at least 80% power to detect large effect
sizes (1.0 to 3.0 mean differences in SD units) based on
two-group comparisons, two-sided tests with 5% significance level. Some experiments including body weight and
food intake were measured repeatedly thus affording larger
statistical power. No replicate samples from in vitro studies
were excluded in the analysis. All data from animal samples
with measurement of study endpoints were included in the
analysis. Experiments with slight differences in animal numbers per group were due to the number of animals that were
successfully bred and not due to exclusion of certain animals
and their data points. Mice within a cage were randomized
to all groups in an experiment to ensure balance in treatment
group assigmnents across all cages. The animals were randomly selected for group assigmnent without preference to
size or other confounding factors. A different individual
performed measurements on study endpoints to ensure
blinding from group assignment. Furthermore, only animal
IDs without information on group assignment were available
to staff performing the endpoint evaluation. Parametric tests
were utilized after evaluating distribution of data (e.g.
percentiles, mean and median levels), test for normality (e.g.
Kolmogorov-Smimov test, if sufficient sample sizes) and
test for homogeneity of variance assumptions across groups.
Otherwise, nonparametric tests were utilized. Appropriateness of other statistical models including linear mixed
models to evaluate trends over time and goodness of fit of
the models using the Akaike Information Criterion (AIC)
and analysis of covariance (ANCOVA) assuming equal
slopes between groups were also evaluated.
All subjects at the MDC-CC baseline examination were
divided into ascending quartiles according to their value of
fasting pro-NT. Body-mass-index (BMI), waist circumference and homeostasis model assessment of insulin resistance
(HOMA-IR) were analyzed as dichotomous outcome variables as defined above. In cross-sectional analyses, the
present inventors related baseline quartile of pro-NT to the
dichotomous outcome of obesity, abdominal obesity, and
insulin resistance using age and sex adjusted logistic regression models. In the analyses of incident obesity, the present
inventors related baseline quartile of pro-NT to the dichotomous outcome of incident obesity using logistic regression
adjusted for baseline age, sex, and BMI. Data are presented
as odds ratios (95% confidence intervals), and subjects
belonging to the lowest quartile of pro-NT were defined as
the referent group (odds ratio=!). 'P for trend' denotes the
P-value for linear trend over quartiles 1-4.
Results:
To examine the potential role of NT in fat deposition and
obesity, the present inventors initially compared NT-deficient mice to their wild type littermates fed a standard diet
(18% kcal from fat) for 6 months. Average body weights,
body length, small bowel weight and length, villus height,
and crypt number did not differ significantly between genotypes (FIG. llA-F). However, at necropsy, the epididymal
and retroperitoneal fat pads of NT_;_ mice were consistently
smaller in size as compared to wild type (FIG. 4A-C), which
prompted further investigation. Indeed, when challenged

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,473,670 B2

25

26

with a high-fat diet (HFD; 60% kcal from fat), the size of
epididymal, retroperitoneal, and pericardiac fat deposits
were markedly smaller in NT- 1- mice compared to wild type
(FIG. 4D-F). Consistent with these differences in fat deposition, as compared to wild type, both male and female
NT_;_ mice fed HFD gained less body weight with significant differences first noted at 9 weeks in males (FIG. lA)
and 16 weeks in females (FIG. 1B). In contrast, no differences in body weight were noted between female NT+!+ and
NT_;_ mice fed a low-fat diet (LFD; 10% kcal from fat)
(FIG. 4G), similar to what was observed in mice fed
standard chow. Echo MRI assessment of total fat (corrected
by body weight) further confirmed that body fat composition
was reduced in NT_;_ mice fed either a HFD or LFD
compared with wild type (FIG. 4H).
Obesity-associated insulin resistance was also attenuated
in NT-deficient mice. On a HFD, NT-deficient mice demonstrated lower levels of fasting plasma glucose and insulin
(FIG. lC), greater insulin sensitivity, and faster glucose
clearance (FIG. lD), as compared with wild type. Additionally, insulin-stimulated p-Akt expression was decreased in
the livers of NT+/+ mice fed HFD, whereas the induction of
p-Akt following injection of insulin in NT- 1- mice fed HFD
was similar to that noted for both wild type and NT-deficient
mice fed LFD (FIG. 12A). In contrast, there was no difference in insulin secretion comparing NT+!+ and NT_;_ mice
maintained on a normal chow diet following either glucose
administration by gavage or refeeding after a 16 h fast
(FIGS. 12B-C). Moreover, hepatic steatosis (assessed by
H&E and oil red O staining) (FIG. lE) and liver triglyceride
(TG) and cholesterol accumulation (FIG. lF) were significantly decreased in NT- 1- mice fed a HFD. Analysis of
adipocytes in epididymal fat pads showed a reduction in size
(FIG. lG-H), and decreased inflammatory infiltrates (FIG.
41) and numbers of macrophages (F4/80-positive cells)
(FIG. 4J) in NT-deficient mice fed a HFD. These results
indicate that NT-deficiency protects against many of the
comorbidities associated with high dietary fat intake.
NT has been linked to hypothalamic leptin signaling and
is considered an anorectic peptide based on acute suppression of food intake in rats following intracerebral or intraperitoneal (i.p.) administration of NT or NT agonists. When
considering total food intake over 22 weeks, there were no
differences between genotypes in either male or female mice
fed with LFD or males fed a HFD; however, a slight 10%
decrease in female NT_;_ mice fed a HFD reached significance (FIG. SA). Weekly food consumption was not statistically different in male or female mice fed with LFD or
males fed with HFD (FIGS. SB-C); only week 9 comparison
in females fed HFD reached significance (FIG. SC). Energy
expenditure, locomotor activity, energy intake, and respiratory exchange ratio (FIGS. SD-G) did not differ significantly
between NT+!+ and NT_;_ mice fed either HFD or LFD.
Therefore, these factors do not appear to contribute to the
lower weight gain observed in NT- 1- mice fed a HFD.
The present inventors next evaluated differences in intestinal lipid absorption as a possible mechanism for the
decreased weight gain noted in NT-deficient mice. Fecal TG
content was increased by 25% in NT_;_ mice fed HFD
compared to NT+!+ littermates (FIG. 2A), but was not
associated with a change in stool color, consistency or output
(FIG. 2A), indicating that NT deficiency decreases lipid
absorption without overt signs of fat malabsorption (i.e.,
steatorrhea). Similarly, less and smaller lipid droplets were

noted in the mucosa of the proximal intestine of NT_;_ mice
at 30 and 60 min after olive oil gavage compared with NT+/+
mice (FIG. 2B). To better track and quantify intestinal
absorption, 13 C 18 -oleic acid (1 3 C 18 -OA) was administered
by gavage and measured in the proximal intestine and
plasma by Fourier transform-mass spectrometry (FTMS). 13 C 18 -OA was significantly decreased in the proximal
intestine and at 2 and 3 h in plasma of NT_;_ mice compared
to wild type (FIG. 2C). NT administration (3600 nmol/kg
body weight, i.p.) restored TG accumulation in NT- 1- mice
to levels similar to those in Nr 1+ mice (FIG. 2D). NT
treatment also increased FA uptake in rat intestinal epithelial- I (RIE-1) cells (FIGS. 7A-B) that express NTRl and 3
[similar to human intestinal cells (FHs 74 INT) and mouse
intestinal mucosa (FIGS. 6A-C)], while siRNA knockdown
of either NTRl or NTR3 reduced NT-mediated FA absorption (FIG. 7C).
Similarly, pretreatment of C57BL/6 mice with SR 48692
(2.5 mg/kg, ip ), a selective nonpeptide NTRl antagonist that
acts peripherally and centrally when administered either ip
or by gavage, decreased intestinal FA absorption following
olive oil gavage (FIG. 13A). To further demonstrate that the
effect of SR 48692 was due to disruption of NT signaling,
the experiment was repeated using NT_;_ mice and their wild
type littermates. As with the C57BL/6 mice, pretreatment
with SR 48692 inhibited intestinal FA absorption in wild
type mice (as measured by TG accumulation). However, SR
pretreatment in NT_;_ mice did not further decrease lipid
absorption after olive oil administration which, as expected,
was significantly decreased compared to wild type mice
(FIG. 13B). These results indicate that SR 48692 attenuation
of fat uptake reflects the disruption of normal NT signaling
and is not due to an unanticipated off-target effect. Consistent with a role for NT in RFD-induced weight gain,
treatment with SR 48692 (2.5 mg/kg, oral gavage, twice a
day) for 13 weeks significantly attenuated body weight gain
in wild type mice fed a HFD (FIG. 13C) without altering
food intake (FIG. 13D). Collectively, these results indicate
that NT promotes intestinal lipid uptake through NTRl and
possibly NTR3 promoting weight gain in mice fed a HFD.
Interestingly, Rabinowich et al. recently demonstrated that
NTR3/sortilin deficient mice, when placed on a HFD, exhibited a similar phenotype as NT-deficient mice, thus further
emphasizing the potential importance of the NT/NTR axis in
weight gain associated with an overabundance of fat.
AMPK, a key fuel-sensing enzyme and a critical regulator
of metabolism, mediates the effects of a variety of hormones.
Phosphorylated-AMPK (p-AMPK) was upregulated in the
proximal intestinal mucosa of NT_;_ mice fed a standard
diet, as compared to wild type mice (FIG. 2E). Alternatively,
p-AMPK expression was decreased in the proximal intestine
of NT+!+ mice after olive oil gavage, although pretreatment
with SR 48692 restored the p-AMPK expression to control
levels (FIG. 2F). Treatment of FHs 74 Int and RIE-1 cells
with oleate also led to an increase in p-AMPK (FIG. 2G),
while pharmacological activation of AMPK with AICAR
(5-aminoimidazole-4-carboxamide- l-~-D-ribofuranoside)
further increased oleate-stimulated p-AMPK (FIG. 2J) and
concomitantly decreased FA absorption (FIG. 2K). However, NT pretreatment of the FHs 74 INT and RIE-1 cells
reduced the p-AMPK increase from oleate (FIG. 2H; FIG.
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7D) and blocked the effects from pharmacological activation
of AMPK with AI CAR. Conversely, either NTRl or NTR3
knockdown (FIG. 21, FIG. 7E) prevented the NT-mediated
suppression of p-AMPK. Knockdown of the upstream
AMPK kinase Ca2 +-calmodulin-dependent protein kinase
kinase (CaMKK2), but not liver kinase Bl (LKBl),
decreased oleate-stimulated p-AMPK (FIG. 2L). Moreover,
overexpression of CaMKK2 attenuated NT-mediated suppression of p-AMPK (FIG. 2M). Together, these findings
suggest that NT, acting through NTRl and/or NTR3
increases FA absorption through suppression of CaMKK2~
mediated AMPK phosphorylation. Furthermore, These findings identify AMPK as a critical regulator of NT release
(throughAMPK activation) and NT-mediated fat absorption
(through AMPK inhibition).
Drosophila provide a powerful model system to better
understand molecular mechanisms regulating human metabolic disorders. To further establish the role of NT on
intestinal lipid absorption and AMPK regulation, the present
inventors expressed human NT in the midgut EE cells of
Drosophila using the EE cell-specific drivers Gr36C-Gal4
(see colocalization with EE-specific transcription factor
Prospero; FIGS. SA-B) or voila-Gal4. As shown in FIGS.
9A-C, mature NT 1 - 13 peptide was detected in larval gut (3.1
fg/gut) and Drosophila S2 cells transfected with NT cDNA.
Compared to control, NT expression markedly increased
lipid droplets in midgut of 7 d adult (FIG. 3A) and larvae
(FIG. SC) fed a standard diet. Increased lipid droplets were
also noted in oenocytes (FIG. 3B) and fat body (FIG. 3C) of
Gr36C-NT 3 rd instar larvae. Next, the present inventors used
a diet-induced obesity model in Drosophila to further delineate the effect of NT in lipid absorption. Increased lipid
droplets were noted in the midgut of wild type flies fed HFD
compared with flies fed normal food (FIG. 3D). NT expression dramatically increased lipid accumulation in the midgut
(FIG. 3D) and total body TG levels (FIG. 3E) with either
normal food or HFD compared with wild type, suggesting
that the role of NT is to promote efficient lipid absorption,
which is further enhanced by increased fat concentration.
Consistently, the present inventors also found that NT
expression decreased gut p-AMPK levels in both Drosophila adult and larvae (FIG. 3F; FIG. SD). Together, these
findings suggest that similar to mice, the effects of NT on
lipid absorption are mediated, in part, through AMPK regulation. Indeed, the present inventors found that AMPK
overexpression decreased, whereas AMPK knockdown
increased lipid droplets in the midgut of7 d adults (FIG. 3G)
and the midgut, fat body and oenocytes of larvae (FIGS.

p-AMPK levels (FIG. lOC). Knockdown of PKl-R expression in ECs using MyolA-Gal4 to drive UAS-CG9918
RNAi (TRiP 27539) expression in flies also expressing NT
driven by the EE cell-specific tachykinin (TK) promoter
markedly attenuated NT-induced lipid droplet accumulation
(FIG. lOD). These results indicate that NT increases lipid
accumulation, at least in part, through PKl-R, an NTR-like
receptor that shares a high degree of sequence similarity
(e.g., 32% identity and 50% similarity) with mouse NTRl
(FIG. lOE), supporting an evolutionarily conserved function
for NTR signaling in lipid storage.
The mouse and Drosophila data prompted the instant
inventors to assess the possible role of NT in the development of obesity and its metabolic complications in humans.
Fasting plasma concentrations of pro-NT were analyzed
from 4,632 middle-aged subjects of the population-based
Malmo Diet and Cancer Study Cardiovascular Cohort (Table
1). The age- and sex-adjusted likelihood of being obese,
abdominally obese, and insulin resistant significantly
increased across quartiles of pro-NT plasma levels (p=0.01,
0.001 and <0.0001, respectively, Table 2). Continuous values of pro-NT were also significantly related to continuous
values of body-mass-index (BMI), waist circumference and
homeostasis model assessment of insulin resistance (Table
3). Among non-obese subjects, the risk of developing obesity during an average follow-up time of 16.5±1.5 years
increased gradually with pro-NT quartiles, independently of
baseline body mass index (BMI), age, and gender
(p<0.0001, Table 2). Importantly, non-obese subjects in the
top quartile of baseline pro-NT levels had greater than
double the risk of developing obesity compared to those in
the lowest quartile (OR=2.05, 95% CI: 1.38-3.06). Whereas
the cross sectional relationship between pro-NT and obesity
became non-significant after additional adjustment for insulin resistance, the prospective relationship between pro-NT
and risk of new-onset obesity remained highly significant
(p=0.001) after adjustment for insulin resistance (data not
shown). Likewise, the top versus bottom quartiles of pro-NT
were associated with an OR=l.34 (95% CI: 1.05, 1.70) for
the risk of being obese, abdominally obese (OR=l.30, 95%
CI: 1.09-1.54), and insulin resistant (OR=l.70, 95% CI:
1.39-2.06). Thus, pro-NT levels strongly predict new onset
obesity in a graded manner, which is independent of baseline
BMI and insulin resistance.
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TABLE 1
Clinical characteristics of the Malmo
Diet and Cancer Cardiovascular Cohort (MDC-CC)

SE-G).

To identify the endogenous Drosophila NTR among the
many G-protein coupled receptors, the present inventors
carried out a targeted RNAi screen in cultured Drosophila
S2 cells; expression of NT or treatment with NT peptide
consistently decreased p-AMPK (FIGS. lOA-B). Among the
three potential Drosophila NTRs, RNAi of CG9918 (Pyrokinin 1 receptor, PKl-R), but not CG8784 or CG8795
blocked the decrease in p-AMPK levels in NT-expressin~
cells (FIG. lOA), suggesting that NT inhibits p-AMPK
activation through PK-IR in S2 cells. This effect does not
appear to be due to interference with PK-1 signaling, since
PK-1 (encoded by Capability) knockdown did not alter

55 Characteristic
Age (years)
Female sex, n (%)
Body Mass Index (kg/m2 )
Waist circumference (cm)
60 Fasting blood glucose (mM)
Fasting insulin concentration (mU/L)
HOMA-IR

65

Value
57.7 ± 6.0
2661 (57.5)
25.8 ± 3.9
84.0 ± 12.9
5.2 ± 1.4
7.0 (4.0-9.0)
1.5 (0.9-2.2)

N
4,626
4,626
4,626
4,625
4,468
4,468
4,468

Data_ are giv~n as mea!1 ± standard devi_atior:i for_normally distributed variables, and as
median and mterquart1le range for fastmg msulm concentration. Categorical data are
presented as numbers (percentages).
"N" denotes the number with complete data, thus, included in analyses.
HOMA-I~ Homeos_tasis Model Assessment of Insulin Resistance (fasting plasma insulin
concentrat10n x fastmg blood glucose concentration/22.5).
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TABLE 2
Fasting plasma concentration of pro-neurotensin (pro-NT) in relation to obesity,
insulin resistance and incidence of new-onset obesity in hwnan subjects (Malm0 Diet
and Cancer Cardiovascular Cohort, MDC-CC)
Odds ratio (95% confidence interval)

Prevalent
obesity
Prevalent
abdominal
obesity
Prevalent
insulin
resistance
New-onset
obesity

N total/N
Cases

Pro-NT
Quartile 1

Pro-NT
Quartile 2

Pro-NT
Quartile 3

Pro-NT
Quartile 4

P for
trend

4626/604

1.0 (ref)
1.0 (ref)

1.13
(0.88-1.45)
1.23
(1.04-1.46)

1.34
(1.05-1.70)
1.30
(1.09-1.54)

0.01

4625/1769

1.00
(0.78-1.29)
1.07
(0.90-1.27)

4468/1140

1.0 (ref)

1.30
(1.06-1.59)

1.43
(1.17-1.74)

1.70
(1.39-2.06)

<0.0001

2594/333

1.0 (ref)

1.41
(0.95-2.10)

1.79
(1.21-2.65)

2.05
(1.38-3.06)

<0.0001

0.001

N total/N cases denotes total number of subjects in the analysis divided by the number of cases with listed
obesity or insulin resistance phenotype.
Pro-NT Quartiles 1-4 define the MDC-CC population quartiles (lowest to highest) with median (range)
baseline fasting plasma pro-NT concentrations (pmoliL) of60.l (3.3-75.9), 89.3 (75.9-105), 123 (105-149)
and 190 (149-1155), respectively.
Data are presented as odds ratios (95% confidence intervals), and subjects belonging to the lowest quartile
of pro-NT were defined as the reference group (odds ratio= 1).
P for trend denotes the P-value for linear trend over quartiles 1-4.

25

TABLE 3
Linear regression models to assess association between continuous
values of log-transformed fasting plasma concentration of proneurotensin (pro-NT) (expressed as per 1 SD increment) in relation
to continuous outcome values of body mass index, waist circwnference
and HOMA-IR in human subjects (Malmo Diet and Cancer
Cardiovascular Cohort, MDC-CC)

Metabolic trait
2

Body Mass Index (per kg/m )
Waist Circumference (per cm)
HOMA-IR (per mmol/L*mU/L)

13-coefficient ± SE
(per SD increment of
log-transformed pro-NT)

p-value

0.14 ± 0.06
0.33 ± 0.15
0.13 ± 0.G15

0.016
0.026
<0.001

HOMA-IR= Homeostasis Model Assessment of insulin resistance;
SD = standard deviation;
SE = standard error;
pro-NT = pro-neurotensin

The present inventors' findings demonstrate a causative
role of NT in high fat diet-induced obesity that involves
decreased AMPK activation and increased intestinal lipid
absorption. Moreover, the present inventors identify
increased pro-NT levels as a strong risk factor of human
obesity, suggesting possible novel avenues of drug development research to either prevent or treat this disorder. From
an evolutionary perspective, metabolically "thrifty" genes,
like NT, are highly beneficial to ensure the efficient absorption of all ingested fats, but with the abundance of fats in
typical Western diets, NT can have a detrimental effect by
contributing to increased fat storage, obesity, and related
metabolic disorders.
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Example 2
A better understanding of the molecular mechanisms
regulating NT secretion is required to delineate the effects of
NT during physiologic and pathologic conditions. The
instant inventors have shown that activation of AMPK
stimulates NT secretion from endocrine cells through the
inhibition of mTORCl and negative feedback activation of
ERKl/2. This example is directed towards showing that
FFA-mediated NT secretion, acting through FFARl and/or

60

65

FFAR4, is regulated by a novel cross-talk mechanism
between the AMPK/mTORCl/ERKl/2 signaling pathways
in intestinal endocrine cells.
Oleic Acid, a Long Chain FFA, Activates AMPK and
Stimulates NT Secretion.
To better delineate the role of FFAs in NT secretion, it was
first determined whether administration of FFAs in vivo
stimulated NT release. As shown in FIG. 14A, fasting
plasma NT levels were significantly increased after gavage
ofolive oil (00) (enriched in oleic acid [OA]) (10 µ1/g body
weight) compared to control mice given saline. Next, it was
determined whether FFAs stimulate NT secretion using
intestinal endocrine cell models that our laboratory has
extensively utilized in the past. These include BON, which
the instant inventors have shown synthesizes and secretes
NT peptide in a manner analogous to that of N cells in the
small bowel and QGP-1, a human somatostatinoma cell line
which expresses high levels of NT and secretes NT in
response to stimulation. Similar to in vivo study, treatment
with OA stimulated NT secretion (measured by an NT
enzyme immunoassay [HA]) in both BON and QGP-1; in
addition, OA treatment increased phosphorylation of AMPK
(p-AMPK) and acetyl-CoA carboxylase (p-ACC, a downstream effector of AMPK) (FIGS. 14B-C).
Treatment with Agonists to FFAR 1 and 4 Increase AMPK
Activity.
FFARl (previously known as GPR40) and FFAR4 (previously known as GPR120) are medium- to long-chain FFA
G-protein-coupled receptors that have been implicated in the
regulation of energy homeostasis and hormone secretion.
The instant inventors have found that the mouse intestinal
endocrine cell line STC-1, which expresses both FFARl and
FFAR4 and has been utilized as a model to study FFAstimulated hormone secretion, contains an abundant amount
of NT vesicles as noted by immunofluorescent (IF) staining
using an anti-NT antibody (FIG. 15A, left panel). Either OA
(0.25 mM) or phorbol myristate acetate (100 nM) (PMA, a
positive control) treatment stimulated NT release from
STC-1 cells (FIG. 15A, middle panel). Interestingly, treatmentwitheither FFARl and FFAR4 agonists (1 µM, 90min)
or OA increased p-AMPK expression (FIG. 15A, right
panel), suggesting the possibility that FFA-stimulated NT
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release andAMPK activation are mediated by FFARl and/or
FFAR4 signaling. Expression ofFFARl and FFAR4 mRNA
in BON and QGP-1 cells was confirmed by real time-PCR
analysis (FIG. 15B), further suggesting the involvement of
both receptors in FFA-regulated NT secretion.
Cross-Talk of AMPK, mTORCl and ERK Signaling.
AMPK activation inhibits mTORCl through raptor, a
component of mTORCl, or TSC2, a negative regulator of
mTORCl signaling. The instant inventors have demonstrated that inhibition of mTORCl signaling enhanced NT
release through feedback activation of ERKl/2 and furthermore, AMPK activation increased NT secretion through
inhibition of mTORCl signaling (FIG. 16A). Consistently,
treatment of BON cells with AICAR, an AMPK activator,
decreased expression of p-S6Kl, a downstream effector of
mTORCl, and increased p-ERKl/2 (FIG. 16B, left panel).
Pretreating cells with compound C (CC), a selective AMPK
inhibitor, attenuated this effect (FIG. 16B, right panel).
Moreover, a stable BON overexpression cell line was generated with a mutant raptor vector in which both Ser722 and
Ser792 (AMPK phosphorylation sites) are replaced by alanine. As shown in FIG. 16C, AICAR-stimulated NT secretion was decreased in cells expressing the mutant raptor
compared to the cells expressing control vector and treated
with AICAR. Additionally, as shown in FIG. 16D, siRNAmediated knockdown ofTSC2 preventedAICAR-stimulated
NT secretion. Together, these findings further indicate the
interaction of AMPK, mTORCl and ERK signaling in the
regulation of NT secretion.
In view thereof, without wishing to be bound by theory,
it is believed that FFA-mediated NT release by EE cells,
through a cross-talk mechanism involving AMPK activation, mTORCl inhibition, and ERKl/2 activation, promotes
intestinal absorption of FFAs acting through NTRl and/or
NTR3 and the inhibition of intestinal AMPK. Moreover, it
is believed that the overconsumption of dietary fats, which
leads to excess NT secretion, results in obesity (from continued fat storage) and metabolic disorders (e.g., hepatic
steatosis and insulin resistance).
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 26
<210> SEQ ID NO 1

5

10

15

20

25

30

35

40

45

50

55
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35
-continued
<211> LENGTH, 345
<212> TYPE, PRT
<213> ORGANISM, Mus musculus
<400> SEQUENCE,

1

Ser Gly Asn Ser Ser Glu Ser Ile Leu Glu Pro Asn Ser Asn Leu Asp
1
5
10
15
Val Asn Thr Asp Ile Tyr Ser Lys Val Leu Val Thr Ala Val Tyr Leu
20
25
30
Ala Leu Phe Val Val Gly Thr Val Gly Asn Ser Val Thr Ala Phe Thr
35
40
45
Leu Ala Arg Lys Lys Ser Leu Gln Ser Leu Gln Ser Thr Val His Tyr
50
55
60
His Leu Gly Ser Leu Ala Leu Ser Asp Leu Leu Ile Leu Leu Leu Ala

65

70

75

80

Met Pro Val Glu Leu Tyr Asn Phe Ile Trp Val His His Pro Trp Ala
85
90
95
Phe Gly Asp Ala Gly Cys Arg Gly Tyr Tyr Phe Leu Arg Asp Ala Cys
100
105
110
Thr Tyr Ala Thr Ala Leu Asn Val Ala Ser Leu Ser Val Glu Arg Tyr
115
120
125
Leu Ala Ile Cys His Pro Phe Lys Ala Arg Thr Leu Met Ser Arg Ser
130
135
140
Arg Thr Lys Lys Phe Ile Ser Ala Ile Trp Leu Ala Ser Ala Leu Leu
145
150
155
160
Ala Val Pro Met Leu Phe Thr Met Gly Leu Gln Asn Arg Ser Ala Asp
165
170
175
Gly Gln His Pro Gly Gly Leu Val Cys Thr Pro Thr Val Asp Thr Ala
180
185
190
Thr Val Lys Val Val Ile Gln Val Asn Thr Phe Met Ser Phe Leu Phe
195
200
205
Pro Met Leu Ile Ile Ser Ile Leu Asn Thr Val Ile Ala Asn Lys Leu
210
215
220
Thr Val Met Val His Gln Ala Ala Glu Gln Gly Arg Gly Val Cys Thr
225
230
235
240
Val Gly Thr His Asn Ser Leu Glu His Ser Thr Phe Asn Met Ser Ile
245
250
255
Glu Pro Gly Arg Val Gln Ala Leu Arg His Gly Val Leu Val Leu Arg
260
265
270
Ala Val Val Ile Ala Phe Val Val Cys Trp Leu Pro Tyr His Val Arg
275
280
285
Arg Leu Met Phe Cys Tyr Ile Ser Asp Glu Gln Trp Thr Thr Phe Leu
290
295
300
Phe Asp Phe Tyr His Tyr Phe Tyr Met Leu Thr Asn Ala Leu Phe Tyr
305
310
315
320
Val Ser Ser Ala Ile Asn Pro Ile Leu Tyr Asn Leu Val Ser Ala Asn
325
330
335
Phe Arg Gln Val Phe Leu Ser Thr Leu
340
345

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 360
TYPE, PRT
ORGANISM, Drosophila melanogaster

<400> SEQUENCE, 2
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38
-continued

Ala Gly Asn Met Ser His Asp Leu Gly Pro Pro Arg Asp Pro Leu Ala
1
5
10
15
Ile Val Ile Pro Val Thr Val Val Tyr Ser Leu Ile Phe Ile Thr Gly
20
25
30
Val Val Gly Asn Ile Ser Thr Cys Ile Val Ile Lys Lys Asn Arg Ser
35
40
45
Met His Thr Ala Thr Asn Tyr Tyr Leu Phe Ser Leu Ala Ile Ser Asp
50
55
60
Phe Leu Leu Leu Leu Ser Gly Val Pro Gln Glu Val Ser Tyr Ile Trp
65
70
75
80
Ser Lys Tyr Pro Tyr Val Phe Gly Glu Tyr Ile Cys Ile Gly Arg Gly
85
90
95
Leu Leu Ala Glu Thr Ser Ala Asn Ala Thr Val Leu Thr Ile Thr Ala
100
105
110

Phe Thr Val Glu Arg Tyr Ile Ala Ile Cys His Pro Phe Leu Gly Gln
115
120
125
Ala Met Ser Lys Leu Ser Arg Ala Ile Arg Ile Ile Val Leu Val Trp
130
135
140
Ile Met Ala Ile Val Thr Ala Ile Pro Gln Ala Ala Gln Phe Gly Ile
145
150
155
160
Glu His Tyr Ser Gly Val Glu Gln Cys Gly Ile Val Arg Val Ile Val
165
170
175
Lys His Ser Phe Gln Leu Ser Thr Phe Ile Phe Phe Leu Ala Pro Met
180
185
190
Ser Ile Ile Leu Val Leu Tyr Leu Leu Ile Gly Val His Leu Tyr Arg
195
200
205
Ser Thr Leu Val Glu Gly Pro Ala Ser Val Ala Arg Arg Gln Gln Leu
210
215
220
Lys Ser Val Pro Ser Asp Thr Ile Leu Tyr Arg Tyr Gly Gly Ser Gly
225
230
235
240
Thr Ala Met Ser Phe Asn Gly Gly Gly Ser Gly Ala Gly Thr Ala Gly
245
250
255
Leu Met Gly Gly Ser Gly Ala Gln Leu Ser Ser Val Arg Gly Arg Leu
260
265
270
Asn His Tyr Gly Thr Arg Arg Val Leu Arg Met Leu Val Ala Val Val
275
280
285

Val Cys Phe Phe Leu Cys Trp Ala Pro Phe His Ala Gln Arg Leu Ile
290
295
300
Ala Ile Tyr Ala Pro Ala Arg Gly Ala Lys Leu Arg Asp Gln His Glu
305
310
315
320
Phe Val Tyr Thr Val Met Thr Tyr Val Ser Gly Val Leu Tyr Tyr Leu
325
330
335
Ser Thr Cys Ile Asn Pro Leu Leu Tyr Asn Ile Met Ser His Lys Phe
340
345
350
Arg Glu Ala Phe Lys Ala Val Leu
355
360

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 3

US 10,473,670 B2
40

39
-continued
tcatcgcctt tgtggtctgc t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 4
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 4
tggttgctgg acacgctgtc g

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 5
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 5
gtctcctcag cttcatcgta t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 6
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 6
tccccaaagc ctgaagctgt a

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 7
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 7
agaatggtcg agactatgtt g

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 8
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 8
aagagctatt ccaagaggtc c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 9
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 9
gagaagcccc caaaattctc

<210> SEQ ID NO 10
<211> LENGTH, 20
<212> TYPE, DNA

20
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-continued
<213> ORGANISM, Artificial
<220> FEATURE,
<223> OTHER INFORMATION, PCR primer
<400> SEQUENCE, 10
caaggaccca gtgcaggtat

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 11
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 11
actcgctcat cttcgcattt

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 12
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 12
tgggaccaca cgaagttgta

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 13
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 13
tttcaagctg tgctttgtgg

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 14
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 14
agttctctga acgggagcaa

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 15
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 15
tcaccaactg ggacgacatg

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 16
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 16
accggagtcc atcacgatg

19

US 10,473,670 B2
43

44
-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 17
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 17
gagtttcaac ggcggaggaa

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 18
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 18
agcagaggaa gaagcacacc

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 19
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 19
ggcgtgctgg gtaatcttat

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 20
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 20
caaaggttgt acagctcctg

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 21
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 21
gctacgccct catatttatc

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 22
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 22
gaggttatag aggtcctgcg

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 23
LENGTH, 18
TYPE, DNA
ORGANISM, Artificial
FEATURE,

20
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45
-continued
<223> OTHER INFORMATION, PCR primer
<400> SEQUENCE, 23
atgaaatcta tgttggtc

<210>
<211>
<212>
<213>
<220>
<223>

18

SEQ ID NO 24
LENGTH, 17
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 24
ccaacgcgcg ggaaggc

<210>
<211>
<212>
<213>
<220>
<223>

17

SEQ ID NO 25
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 25
gcgtcggtca attcaatctt

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 26
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, PCR primer

<400> SEQUENCE, 26
20

aagctgcaac ctcttcgtca

What is claimed is:
1. A method of predicting increased risk of obesity in a
non-obese subject, comprising:
(a) obtaining a biological sample from the non-obese
subject;
(b) detecting an amount of neurotensin in the biological
sample;
(c) detecting the phosphorylation level of adenosine
monophosphate-activated protein kinase (AMPK) in
the biological sample;
(d) determining that the subject has an increased risk of
obesity if there is an increased amount of neurotensin
and a decreased amount of AMPK phosphorylation in
the sample as compared to normal levels; and
(e) administering an effective amount of a neurotensin
inhibitor; wherein the neurotensin inhibitor is an NTRl
antagonist.
2. The method of claim 1, wherein the neurotensin is
pro-neurotensin.
3. The method of claim 2, wherein the amount of proneurotensin is detected by a technique comprising RNA
measuring assays and protein measuring assays.
4. The method of claim 3, wherein the RNA measuring
assay comprises real time reverse transcription polymerase
chain reaction.
5. The method of claim 1, wherein the risk of becoming
obese is independent of baseline body mass index.
6. The method of claim 1, wherein the biological sample
comprises blood, plasma, serum, plasma, and tissue.

40

45

50

55

60

65

7. The method of claim 1, wherein the obesity is prevalent
obesity.
8. The method of claim 1, wherein the obesity is prevalent
abdominal obesity.
9. The method of claim 1, wherein the obesity is newonset obesity.
10. A method of predicting increased risk of obesity in a
non-obese subject, comprising:
(a) obtaining a biological sample from the non-obese
subject;
(b) detecting an amount of neurotensin in the biological
sample;
(c) detecting the phosphorylation level of adenosine
monophosphate-activated protein kinase (AMPK) in
the biological sample;
(d) determining that the subject has an increased risk of
obesity if there is an increased amount of neurotensin
and a decreased amount of AMPK phosphorylation in
the sample as compared to normal levels; and
(e) administering an effective amount of a neurotensin
inhibitor; wherein the neurotensin inhibitor is a nonpeptide NTRl antagonist.
11. The method of claim 10, wherein the neurotensin is
pro-neurotensin.
12. The method of claim 11, wherein the amount of
pro-neurotensin is detected by a technique comprising RNA
measuring assays and protein measuring assays.
13. The method of claim 10, wherein the risk of becoming
obese is independent of baseline body mass index.

US 10,473,670 B2
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14. The method of claim 10, wherein the
sample comprises blood, plasma, serum, plasma,
15. The method of claim 10, wherein the
prevalent obesity.
16. The method of claim 10, wherein the
prevalent abdominal obesity.
17. The method of claim 10, wherein the
new-onset obesity.

* * * * *
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